#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Adolescent cannabis use and brain systems supporting adult working memory encoding, maintenance, and retrieval Given prior reports of adverse effects of cannabis use on working memory, an executive function with a protracted developmental course during adolescence, we examined associations between developmental patterns of cannabis use and adult working memory (WM) processes.
1-1	0-10	Adolescent	_
1-2	11-19	cannabis	_
1-3	20-23	use	_
1-4	24-27	and	_
1-5	28-33	brain	_
1-6	34-41	systems	_
1-7	42-52	supporting	_
1-8	53-58	adult	_
1-9	59-66	working	_
1-10	67-73	memory	_
1-11	74-82	encoding	_
1-12	83-84	,	_
1-13	85-96	maintenance	_
1-14	97-98	,	_
1-15	99-102	and	_
1-16	103-112	retrieval	_
1-17	113-118	Given	_
1-18	119-124	prior	_
1-19	125-132	reports	_
1-20	133-135	of	_
1-21	136-143	adverse	_
1-22	144-151	effects	_
1-23	152-154	of	_
1-24	155-163	cannabis	_
1-25	164-167	use	_
1-26	168-170	on	_
1-27	171-178	working	_
1-28	179-185	memory	_
1-29	186-187	,	_
1-30	188-190	an	_
1-31	191-200	executive	_
1-32	201-209	function	_
1-33	210-214	with	_
1-34	215-216	a	_
1-35	217-227	protracted	_
1-36	228-241	developmental	_
1-37	242-248	course	_
1-38	249-255	during	_
1-39	256-267	adolescence	_
1-40	268-269	,	_
1-41	270-272	we	_
1-42	273-281	examined	_
1-43	282-294	associations	_
1-44	295-302	between	_
1-45	303-316	developmental	_
1-46	317-325	patterns	_
1-47	326-328	of	_
1-48	329-337	cannabis	_
1-49	338-341	use	_
1-50	342-345	and	_
1-51	346-351	adult	_
1-52	352-359	working	_
1-53	360-366	memory	_
1-54	367-368	(	_
1-55	369-371	WM	_
1-56	372-373	)	_
1-57	374-383	processes	_
1-58	384-385	.	_

Text=Seventy-five adults with longitudinal assessments of cannabis use (60 with reported use, 15 with no reported use) and prenatal drug exposure assessment completed a spatial WM task during fMRI at age 28.
2-1	386-398	Seventy-five	_
2-2	399-405	adults	_
2-3	406-410	with	_
2-4	411-423	longitudinal	_
2-5	424-435	assessments	_
2-6	436-438	of	_
2-7	439-447	cannabis	_
2-8	448-451	use	_
2-9	452-453	(	_
2-10	454-456	60	_
2-11	457-461	with	_
2-12	462-470	reported	_
2-13	471-474	use	_
2-14	475-476	,	_
2-15	477-479	15	_
2-16	480-484	with	_
2-17	485-487	no	_
2-18	488-496	reported	_
2-19	497-500	use	_
2-20	501-502	)	_
2-21	503-506	and	_
2-22	507-515	prenatal	_
2-23	516-520	drug	_
2-24	521-529	exposure	_
2-25	530-540	assessment	_
2-26	541-550	completed	_
2-27	551-552	a	_
2-28	553-560	spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
2-29	561-563	WM	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
2-30	564-568	task	_
2-31	569-575	during	_
2-32	576-580	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-33	581-583	at	_
2-34	584-587	age	_
2-35	588-590	28	_
2-36	591-592	.	_

Text=All subjects passed a multi-drug urine screen on the day of testing and denied recreational drug use in the past week.
3-1	593-596	All	_
3-2	597-605	subjects	_
3-3	606-612	passed	_
3-4	613-614	a	_
3-5	615-625	multi-drug	_
3-6	626-631	urine	_
3-7	632-638	screen	_
3-8	639-641	on	_
3-9	642-645	the	_
3-10	646-649	day	_
3-11	650-652	of	_
3-12	653-660	testing	_
3-13	661-664	and	_
3-14	665-671	denied	_
3-15	672-684	recreational	_
3-16	685-689	drug	_
3-17	690-693	use	_
3-18	694-696	in	_
3-19	697-700	the	_
3-20	701-705	past	_
3-21	706-710	week	_
3-22	711-712	.	_

Text=A fast event-related design with partial trials was used to separate the BOLD response associated with encoding, maintenance, and retrieval periods of the WM task.
4-1	713-714	A	_
4-2	715-719	fast	_
4-3	720-733	event-related	_
4-4	734-740	design	_
4-5	741-745	with	_
4-6	746-753	partial	_
4-7	754-760	trials	_
4-8	761-764	was	_
4-9	765-769	used	_
4-10	770-772	to	_
4-11	773-781	separate	_
4-12	782-785	the	_
4-13	786-790	BOLD	_
4-14	791-799	response	_
4-15	800-810	associated	_
4-16	811-815	with	_
4-17	816-824	encoding	_
4-18	825-826	,	_
4-19	827-838	maintenance	_
4-20	839-840	,	_
4-21	841-844	and	_
4-22	845-854	retrieval	_
4-23	855-862	periods	_
4-24	863-865	of	_
4-25	866-869	the	_
4-26	870-872	WM	_
4-27	873-877	task	_
4-28	878-879	.	_

Text=Behavioral results showed that subjects who began using cannabis earlier in adolescence had longer reaction times (RT) than those with later initiation.
5-1	880-890	Behavioral	_
5-2	891-898	results	_
5-3	899-905	showed	_
5-4	906-910	that	_
5-5	911-919	subjects	_
5-6	920-923	who	_
5-7	924-929	began	_
5-8	930-935	using	_
5-9	936-944	cannabis	_
5-10	945-952	earlier	_
5-11	953-955	in	_
5-12	956-967	adolescence	_
5-13	968-971	had	_
5-14	972-978	longer	_
5-15	979-987	reaction	_
5-16	988-993	times	_
5-17	994-995	(	_
5-18	996-998	RT	_
5-19	999-1000	)	_
5-20	1001-1005	than	_
5-21	1006-1011	those	_
5-22	1012-1016	with	_
5-23	1017-1022	later	_
5-24	1023-1033	initiation	_
5-25	1034-1035	.	_

Text=Cannabis age of onset was further associated with reduced posterior parietal cortex (PPC) encoding BOLD activation, which significantly mediated age of onset WM RT associations.
6-1	1036-1044	Cannabis	_
6-2	1045-1048	age	_
6-3	1049-1051	of	_
6-4	1052-1057	onset	_
6-5	1058-1061	was	_
6-6	1062-1069	further	_
6-7	1070-1080	associated	_
6-8	1081-1085	with	_
6-9	1086-1093	reduced	_
6-10	1094-1103	posterior	_
6-11	1104-1112	parietal	_
6-12	1113-1119	cortex	_
6-13	1120-1121	(	_
6-14	1122-1125	PPC	_
6-15	1126-1127	)	_
6-16	1128-1136	encoding	_
6-17	1137-1141	BOLD	_
6-18	1142-1152	activation	_
6-19	1153-1154	,	_
6-20	1155-1160	which	_
6-21	1161-1174	significantly	_
6-22	1175-1183	mediated	_
6-23	1184-1187	age	_
6-24	1188-1190	of	_
6-25	1191-1196	onset	_
6-26	1197-1199	WM	_
6-27	1200-1202	RT	_
6-28	1203-1215	associations	_
6-29	1216-1217	.	_

Text=However, cannabis age of onset brain-behavior associations did not differ between groups with a single reported use and those with repeated use, suggesting age of onset effects may reflect substance use risk characteristics rather than a developmentally-timed cannabis exposure effect.
7-1	1218-1225	However	_
7-2	1226-1227	,	_
7-3	1228-1236	cannabis	_
7-4	1237-1240	age	_
7-5	1241-1243	of	_
7-6	1244-1249	onset	_
7-7	1250-1264	brain-behavior	_
7-8	1265-1277	associations	_
7-9	1278-1281	did	_
7-10	1282-1285	not	_
7-11	1286-1292	differ	_
7-12	1293-1300	between	_
7-13	1301-1307	groups	_
7-14	1308-1312	with	_
7-15	1313-1314	a	_
7-16	1315-1321	single	_
7-17	1322-1330	reported	_
7-18	1331-1334	use	_
7-19	1335-1338	and	_
7-20	1339-1344	those	_
7-21	1345-1349	with	_
7-22	1350-1358	repeated	_
7-23	1359-1362	use	_
7-24	1363-1364	,	_
7-25	1365-1375	suggesting	_
7-26	1376-1379	age	_
7-27	1380-1382	of	_
7-28	1383-1388	onset	_
7-29	1389-1396	effects	_
7-30	1397-1400	may	_
7-31	1401-1408	reflect	_
7-32	1409-1418	substance	_
7-33	1419-1422	use	_
7-34	1423-1427	risk	_
7-35	1428-1443	characteristics	_
7-36	1444-1450	rather	_
7-37	1451-1455	than	_
7-38	1456-1457	a	_
7-39	1458-1479	developmentally-timed	_
7-40	1480-1488	cannabis	_
7-41	1489-1497	exposure	_
7-42	1498-1504	effect	_
7-43	1505-1506	.	_

Text=Within repeated cannabis users, greater levels of total cannabis use were associated with performance-related increases in dorsolateral prefrontal cortex (DLPFC) activation during maintenance.
8-1	1507-1513	Within	_
8-2	1514-1522	repeated	_
8-3	1523-1531	cannabis	_
8-4	1532-1537	users	_
8-5	1538-1539	,	_
8-6	1540-1547	greater	_
8-7	1548-1554	levels	_
8-8	1555-1557	of	_
8-9	1558-1563	total	_
8-10	1564-1572	cannabis	_
8-11	1573-1576	use	_
8-12	1577-1581	were	_
8-13	1582-1592	associated	_
8-14	1593-1597	with	_
8-15	1598-1617	performance-related	_
8-16	1618-1627	increases	_
8-17	1628-1630	in	_
8-18	1631-1643	dorsolateral	_
8-19	1644-1654	prefrontal	_
8-20	1655-1661	cortex	_
8-21	1662-1663	(	_
8-22	1664-1669	DLPFC	_
8-23	1670-1671	)	_
8-24	1672-1682	activation	_
8-25	1683-1689	during	_
8-26	1690-1701	maintenance	_
8-27	1702-1703	.	_

Text=This pattern of significant results remained unchanged with inclusion of demographic and prenatal measures as covariates.
9-1	1704-1708	This	_
9-2	1709-1716	pattern	_
9-3	1717-1719	of	_
9-4	1720-1731	significant	_
9-5	1732-1739	results	_
9-6	1740-1748	remained	_
9-7	1749-1758	unchanged	_
9-8	1759-1763	with	_
9-9	1764-1773	inclusion	_
9-10	1774-1776	of	_
9-11	1777-1788	demographic	_
9-12	1789-1792	and	_
9-13	1793-1801	prenatal	_
9-14	1802-1810	measures	_
9-15	1811-1813	as	_
9-16	1814-1824	covariates	_
9-17	1825-1826	.	_

Text=Surprisingly, however, at the group level, cannabis users generally performed better than participants who reported never using cannabis (faster RT, higher accuracy).
10-1	1827-1839	Surprisingly	_
10-2	1840-1841	,	_
10-3	1842-1849	however	_
10-4	1850-1851	,	_
10-5	1852-1854	at	_
10-6	1855-1858	the	_
10-7	1859-1864	group	_
10-8	1865-1870	level	_
10-9	1871-1872	,	_
10-10	1873-1881	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
10-11	1882-1887	users	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
10-12	1888-1897	generally	_
10-13	1898-1907	performed	_
10-14	1908-1914	better	_
10-15	1915-1919	than	_
10-16	1920-1932	participants	_
10-17	1933-1936	who	_
10-18	1937-1945	reported	_
10-19	1946-1951	never	_
10-20	1952-1957	using	_
10-21	1958-1966	cannabis	_
10-22	1967-1968	(	_
10-23	1969-1975	faster	_
10-24	1976-1978	RT	_
10-25	1979-1980	,	_
10-26	1981-1987	higher	_
10-27	1988-1996	accuracy	_
10-28	1997-1998	)	_
10-29	1999-2000	.	_

Text=We extend previous investigations by identifying that WM associations with cannabis age of onset may be primary to PPC stimulus encoding activity, while the amount of cannabis use is associated with DLPFC maintenance processes.
11-1	2001-2003	We	_
11-2	2004-2010	extend	_
11-3	2011-2019	previous	_
11-4	2020-2034	investigations	_
11-5	2035-2037	by	_
11-6	2038-2049	identifying	_
11-7	2050-2054	that	_
11-8	2055-2057	WM	_
11-9	2058-2070	associations	_
11-10	2071-2075	with	_
11-11	2076-2084	cannabis	_
11-12	2085-2088	age	_
11-13	2089-2091	of	_
11-14	2092-2097	onset	_
11-15	2098-2101	may	_
11-16	2102-2104	be	_
11-17	2105-2112	primary	_
11-18	2113-2115	to	_
11-19	2116-2119	PPC	_
11-20	2120-2128	stimulus	_
11-21	2129-2137	encoding	_
11-22	2138-2146	activity	_
11-23	2147-2148	,	_
11-24	2149-2154	while	_
11-25	2155-2158	the	_
11-26	2159-2165	amount	_
11-27	2166-2168	of	_
11-28	2169-2177	cannabis	_
11-29	2178-2181	use	_
11-30	2182-2184	is	_
11-31	2185-2195	associated	_
11-32	2196-2200	with	_
11-33	2201-2206	DLPFC	_
11-34	2207-2218	maintenance	_
11-35	2219-2228	processes	_
11-36	2229-2230	.	_

Text=Poorer performance of participants who reported never using cannabis and the consistency of cannabis age of onset associations across single and repeated users limit interpretation of direct developmental effects of cannabis on WM in adulthood.
12-1	2231-2237	Poorer	_
12-2	2238-2249	performance	_
12-3	2250-2252	of	_
12-4	2253-2265	participants	_
12-5	2266-2269	who	_
12-6	2270-2278	reported	_
12-7	2279-2284	never	_
12-8	2285-2290	using	_
12-9	2291-2299	cannabis	_
12-10	2300-2303	and	_
12-11	2304-2307	the	_
12-12	2308-2319	consistency	_
12-13	2320-2322	of	_
12-14	2323-2331	cannabis	_
12-15	2332-2335	age	_
12-16	2336-2338	of	_
12-17	2339-2344	onset	_
12-18	2345-2357	associations	_
12-19	2358-2364	across	_
12-20	2365-2371	single	_
12-21	2372-2375	and	_
12-22	2376-2384	repeated	_
12-23	2385-2390	users	_
12-24	2391-2396	limit	_
12-25	2397-2411	interpretation	_
12-26	2412-2414	of	_
12-27	2415-2421	direct	_
12-28	2422-2435	developmental	_
12-29	2436-2443	effects	_
12-30	2444-2446	of	_
12-31	2447-2455	cannabis	_
12-32	2456-2458	on	_
12-33	2459-2461	WM	_
12-34	2462-2464	in	_
12-35	2465-2474	adulthood	_
12-36	2475-2476	.	_

Text=Methods and materials Participants Participants were drawn from the Maternal Health Practices and Child Development Project (MHPCD), a longitudinal, prospective cohort study of the effects of prenatal drug exposure on children from low-income families in Pittsburgh, PA (cf.,).
13-1	2477-2484	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	2485-2488	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	2489-2498	materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	2499-2511	Participants	_
13-5	2512-2524	Participants	_
13-6	2525-2529	were	_
13-7	2530-2535	drawn	_
13-8	2536-2540	from	_
13-9	2541-2544	the	_
13-10	2545-2553	Maternal	http://maven.renci.org/NeuroBridge/neurobridge#HealthStatusQuestionnaire
13-11	2554-2560	Health	http://maven.renci.org/NeuroBridge/neurobridge#HealthStatusQuestionnaire
13-12	2561-2570	Practices	http://maven.renci.org/NeuroBridge/neurobridge#HealthStatusQuestionnaire
13-13	2571-2574	and	_
13-14	2575-2580	Child	_
13-15	2581-2592	Development	_
13-16	2593-2600	Project	_
13-17	2601-2602	(	_
13-18	2603-2608	MHPCD	_
13-19	2609-2610	)	_
13-20	2611-2612	,	_
13-21	2613-2614	a	_
13-22	2615-2627	longitudinal	_
13-23	2628-2629	,	_
13-24	2630-2641	prospective	_
13-25	2642-2648	cohort	_
13-26	2649-2654	study	_
13-27	2655-2657	of	_
13-28	2658-2661	the	_
13-29	2662-2669	effects	_
13-30	2670-2672	of	_
13-31	2673-2681	prenatal	_
13-32	2682-2686	drug	_
13-33	2687-2695	exposure	_
13-34	2696-2698	on	_
13-35	2699-2707	children	_
13-36	2708-2712	from	_
13-37	2713-2723	low-income	_
13-38	2724-2732	families	_
13-39	2733-2735	in	_
13-40	2736-2746	Pittsburgh	_
13-41	2747-2748	,	_
13-42	2749-2751	PA	_
13-43	2752-2753	(	_
13-44	2754-2757	cf.	_
13-45	2758-2759	,	_
13-46	2760-2761	)	_
13-47	2762-2763	.	_

Text=From this larger cohort, 86 subjects were eligible based upon exclusion criteria and consented (see below) and 75 subjects successfully completed neuroimaging protocols at age 28.
14-1	2764-2768	From	_
14-2	2769-2773	this	_
14-3	2774-2780	larger	_
14-4	2781-2787	cohort	_
14-5	2788-2789	,	_
14-6	2790-2792	86	_
14-7	2793-2801	subjects	_
14-8	2802-2806	were	_
14-9	2807-2815	eligible	_
14-10	2816-2821	based	_
14-11	2822-2826	upon	_
14-12	2827-2836	exclusion	_
14-13	2837-2845	criteria	_
14-14	2846-2849	and	_
14-15	2850-2859	consented	_
14-16	2860-2861	(	_
14-17	2862-2865	see	_
14-18	2866-2871	below	_
14-19	2872-2873	)	_
14-20	2874-2877	and	_
14-21	2878-2880	75	_
14-22	2881-2889	subjects	_
14-23	2890-2902	successfully	_
14-24	2903-2912	completed	_
14-25	2913-2925	neuroimaging	_
14-26	2926-2935	protocols	_
14-27	2936-2938	at	_
14-28	2939-2942	age	_
14-29	2943-2945	28	_
14-30	2946-2947	.	_

Text=Reasons for unsuccessful neuroimaging protocols were claustrophobia during acquisition (n = 3), follow-up report of metal in the body (n = 1), positive pregnancy test (n = 1), THC positive urine screen on the day of neuroimaging (n = 2), current psychiatric medication (n = 2), and non-compliance (n = 2).
15-1	2948-2955	Reasons	_
15-2	2956-2959	for	_
15-3	2960-2972	unsuccessful	_
15-4	2973-2985	neuroimaging	_
15-5	2986-2995	protocols	_
15-6	2996-3000	were	_
15-7	3001-3015	claustrophobia	_
15-8	3016-3022	during	_
15-9	3023-3034	acquisition	_
15-10	3035-3036	(	_
15-11	3037-3038	n	_
15-12	3039-3040	=	_
15-13	3041-3042	3	_
15-14	3043-3044	)	_
15-15	3045-3046	,	_
15-16	3047-3056	follow-up	_
15-17	3057-3063	report	_
15-18	3064-3066	of	_
15-19	3067-3072	metal	_
15-20	3073-3075	in	_
15-21	3076-3079	the	_
15-22	3080-3084	body	_
15-23	3085-3086	(	_
15-24	3087-3088	n	_
15-25	3089-3090	=	_
15-26	3091-3092	1	_
15-27	3093-3094	)	_
15-28	3095-3096	,	_
15-29	3097-3105	positive	_
15-30	3106-3115	pregnancy	_
15-31	3116-3120	test	_
15-32	3121-3122	(	_
15-33	3123-3124	n	_
15-34	3125-3126	=	_
15-35	3127-3128	1	_
15-36	3129-3130	)	_
15-37	3131-3132	,	_
15-38	3133-3136	THC	_
15-39	3137-3145	positive	_
15-40	3146-3151	urine	_
15-41	3152-3158	screen	_
15-42	3159-3161	on	_
15-43	3162-3165	the	_
15-44	3166-3169	day	_
15-45	3170-3172	of	_
15-46	3173-3185	neuroimaging	_
15-47	3186-3187	(	_
15-48	3188-3189	n	_
15-49	3190-3191	=	_
15-50	3192-3193	2	_
15-51	3194-3195	)	_
15-52	3196-3197	,	_
15-53	3198-3205	current	_
15-54	3206-3217	psychiatric	_
15-55	3218-3228	medication	_
15-56	3229-3230	(	_
15-57	3231-3232	n	_
15-58	3233-3234	=	_
15-59	3235-3236	2	_
15-60	3237-3238	)	_
15-61	3239-3240	,	_
15-62	3241-3244	and	_
15-63	3245-3259	non-compliance	_
15-64	3260-3261	(	_
15-65	3262-3263	n	_
15-66	3264-3265	=	_
15-67	3266-3267	2	_
15-68	3268-3269	)	_
15-69	3270-3271	.	_

Text=Study exclusion criteria included childhood (age 10) IQ scores below 80, current psychiatric disorder (assessed with the Mini International Neuropsychiatric Interview) or current psychiatric medication, past head injury with loss of consciousness, and MRI contraindications, including pregnancy, claustrophobia, and non-removable metal in the body.
16-1	3272-3277	Study	_
16-2	3278-3287	exclusion	_
16-3	3288-3296	criteria	_
16-4	3297-3305	included	_
16-5	3306-3315	childhood	_
16-6	3316-3317	(	_
16-7	3318-3321	age	_
16-8	3322-3324	10	_
16-9	3325-3326	)	_
16-10	3327-3329	IQ	_
16-11	3330-3336	scores	_
16-12	3337-3342	below	_
16-13	3343-3345	80	_
16-14	3346-3347	,	_
16-15	3348-3355	current	_
16-16	3356-3367	psychiatric	_
16-17	3368-3376	disorder	_
16-18	3377-3378	(	_
16-19	3379-3387	assessed	_
16-20	3388-3392	with	_
16-21	3393-3396	the	_
16-22	3397-3401	Mini	_
16-23	3402-3415	International	_
16-24	3416-3432	Neuropsychiatric	_
16-25	3433-3442	Interview	_
16-26	3443-3444	)	_
16-27	3445-3447	or	_
16-28	3448-3455	current	_
16-29	3456-3467	psychiatric	_
16-30	3468-3478	medication	_
16-31	3479-3480	,	_
16-32	3481-3485	past	_
16-33	3486-3490	head	_
16-34	3491-3497	injury	_
16-35	3498-3502	with	_
16-36	3503-3507	loss	_
16-37	3508-3510	of	_
16-38	3511-3524	consciousness	_
16-39	3525-3526	,	_
16-40	3527-3530	and	_
16-41	3531-3534	MRI	_
16-42	3535-3552	contraindications	_
16-43	3553-3554	,	_
16-44	3555-3564	including	_
16-45	3565-3574	pregnancy	_
16-46	3575-3576	,	_
16-47	3577-3591	claustrophobia	_
16-48	3592-3593	,	_
16-49	3594-3597	and	_
16-50	3598-3611	non-removable	_
16-51	3612-3617	metal	_
16-52	3618-3620	in	_
16-53	3621-3624	the	_
16-54	3625-3629	body	_
16-55	3630-3631	.	_

Text=One subject only completed three of four fMRI runs and was consequently excluded from fMRI analysis.
17-1	3632-3635	One	_
17-2	3636-3643	subject	_
17-3	3644-3648	only	_
17-4	3649-3658	completed	_
17-5	3659-3664	three	_
17-6	3665-3667	of	_
17-7	3668-3672	four	_
17-8	3673-3677	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
17-9	3678-3682	runs	_
17-10	3683-3686	and	_
17-11	3687-3690	was	_
17-12	3691-3703	consequently	_
17-13	3704-3712	excluded	_
17-14	3713-3717	from	_
17-15	3718-3722	fMRI	_
17-16	3723-3731	analysis	_
17-17	3732-3733	.	_

Text=The Institutional Review Board at the University of Pittsburgh approved this study.
18-1	3734-3737	The	_
18-2	3738-3751	Institutional	_
18-3	3752-3758	Review	_
18-4	3759-3764	Board	_
18-5	3765-3767	at	_
18-6	3768-3771	the	_
18-7	3772-3782	University	_
18-8	3783-3785	of	_
18-9	3786-3796	Pittsburgh	_
18-10	3797-3805	approved	_
18-11	3806-3810	this	_
18-12	3811-3816	study	_
18-13	3817-3818	.	_

Text=Measures Cannabis use The MHCPD substance use assessment procedure (detailed in) was designed to maximize honest and accurate substance use self-report.
19-1	3819-3827	Measures	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
19-2	3828-3836	Cannabis	_
19-3	3837-3840	use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
19-4	3841-3844	The	_
19-5	3845-3850	MHCPD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
19-6	3851-3860	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
19-7	3861-3864	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
19-8	3865-3875	assessment	_
19-9	3876-3885	procedure	_
19-10	3886-3887	(	_
19-11	3888-3896	detailed	_
19-12	3897-3899	in	_
19-13	3900-3901	)	_
19-14	3902-3905	was	_
19-15	3906-3914	designed	_
19-16	3915-3917	to	_
19-17	3918-3926	maximize	_
19-18	3927-3933	honest	_
19-19	3934-3937	and	_
19-20	3938-3946	accurate	_
19-21	3947-3956	substance	_
19-22	3957-3960	use	_
19-23	3961-3972	self-report	_
19-24	3973-3974	.	_

Text=Cannabis use was assessed at previous assessment phases at 14-, 16-, and 22-years-old, and at the time of testing (28-years-old).
20-1	3975-3983	Cannabis	_
20-2	3984-3987	use	_
20-3	3988-3991	was	_
20-4	3992-4000	assessed	_
20-5	4001-4003	at	_
20-6	4004-4012	previous	_
20-7	4013-4023	assessment	_
20-8	4024-4030	phases	_
20-9	4031-4033	at	_
20-10	4034-4037	14-	_
20-11	4038-4039	,	_
20-12	4040-4043	16-	_
20-13	4044-4045	,	_
20-14	4046-4049	and	_
20-15	4050-4062	22-years-old	_
20-16	4063-4064	,	_
20-17	4065-4068	and	_
20-18	4069-4071	at	_
20-19	4072-4075	the	_
20-20	4076-4080	time	_
20-21	4081-4083	of	_
20-22	4084-4091	testing	_
20-23	4092-4093	(	_
20-24	4094-4106	28-years-old	_
20-25	4107-4108	)	_
20-26	4109-4110	.	_

Text=At each visit, cannabis age of onset was obtained (“ How old were you when you first tried marijuana? ”).
21-1	4111-4113	At	_
21-2	4114-4118	each	_
21-3	4119-4124	visit	_
21-4	4125-4126	,	_
21-5	4127-4135	cannabis	_
21-6	4136-4139	age	_
21-7	4140-4142	of	_
21-8	4143-4148	onset	_
21-9	4149-4152	was	_
21-10	4153-4161	obtained	_
21-11	4162-4163	(	_
21-12	4164-4165	“	_
21-13	4166-4169	How	_
21-14	4170-4173	old	_
21-15	4174-4178	were	_
21-16	4179-4182	you	_
21-17	4183-4187	when	_
21-18	4188-4191	you	_
21-19	4192-4197	first	_
21-20	4198-4203	tried	_
21-21	4204-4213	marijuana	_
21-22	4214-4215	?	_
21-23	4216-4217	”	_
21-24	4218-4219	)	_
21-25	4220-4221	.	_

Text=Quantity of cannabis use was assessed through self-report of the usual dose over the past year at each assessment phase.
22-1	4222-4230	Quantity	_
22-2	4231-4233	of	_
22-3	4234-4242	cannabis	_
22-4	4243-4246	use	_
22-5	4247-4250	was	_
22-6	4251-4259	assessed	_
22-7	4260-4267	through	_
22-8	4268-4279	self-report	_
22-9	4280-4282	of	_
22-10	4283-4286	the	_
22-11	4287-4292	usual	_
22-12	4293-4297	dose	_
22-13	4298-4302	over	_
22-14	4303-4306	the	_
22-15	4307-4311	past	_
22-16	4312-4316	year	_
22-17	4317-4319	at	_
22-18	4320-4324	each	_
22-19	4325-4335	assessment	_
22-20	4336-4341	phase	_
22-21	4342-4343	.	_

Text=As in previous work from the MHCPD, all consumption was converted to a dose of marijuana joints based on THC estimates from previous literature.
23-1	4344-4346	As	_
23-2	4347-4349	in	_
23-3	4350-4358	previous	_
23-4	4359-4363	work	_
23-5	4364-4368	from	_
23-6	4369-4372	the	_
23-7	4373-4378	MHCPD	_
23-8	4379-4380	,	_
23-9	4381-4384	all	_
23-10	4385-4396	consumption	_
23-11	4397-4400	was	_
23-12	4401-4410	converted	_
23-13	4411-4413	to	_
23-14	4414-4415	a	_
23-15	4416-4420	dose	_
23-16	4421-4423	of	_
23-17	4424-4433	marijuana	_
23-18	4434-4440	joints	_
23-19	4441-4446	based	_
23-20	4447-4449	on	_
23-21	4450-4453	THC	_
23-22	4454-4463	estimates	_
23-23	4464-4468	from	_
23-24	4469-4477	previous	_
23-25	4478-4488	literature	_
23-26	4489-4490	.	_

Text=For example, reported hashish dose was counted as equivalent to three joints of marijuana; a blunt of was counted as four joints.
24-1	4491-4494	For	_
24-2	4495-4502	example	_
24-3	4503-4504	,	_
24-4	4505-4513	reported	_
24-5	4514-4521	hashish	_
24-6	4522-4526	dose	_
24-7	4527-4530	was	_
24-8	4531-4538	counted	_
24-9	4539-4541	as	_
24-10	4542-4552	equivalent	_
24-11	4553-4555	to	_
24-12	4556-4561	three	_
24-13	4562-4568	joints	_
24-14	4569-4571	of	_
24-15	4572-4581	marijuana	_
24-16	4582-4583	;	_
24-17	4584-4585	a	_
24-18	4586-4591	blunt	_
24-19	4592-4594	of	_
24-20	4595-4598	was	_
24-21	4599-4606	counted	_
24-22	4607-4609	as	_
24-23	4610-4614	four	_
24-24	4615-4621	joints	_
24-25	4622-4623	.	_

Text=Frequency of the usual quantity of use was also obtained over the past year at each assessment phase (every day, 3–4 times per week, 1–2 times per week, once per month, 6–11 times per year, 1–5 times per year, no use).
25-1	4624-4633	Frequency	_
25-2	4634-4636	of	_
25-3	4637-4640	the	_
25-4	4641-4646	usual	_
25-5	4647-4655	quantity	_
25-6	4656-4658	of	_
25-7	4659-4662	use	_
25-8	4663-4666	was	_
25-9	4667-4671	also	_
25-10	4672-4680	obtained	_
25-11	4681-4685	over	_
25-12	4686-4689	the	_
25-13	4690-4694	past	_
25-14	4695-4699	year	_
25-15	4700-4702	at	_
25-16	4703-4707	each	_
25-17	4708-4718	assessment	_
25-18	4719-4724	phase	_
25-19	4725-4726	(	_
25-20	4727-4732	every	_
25-21	4733-4736	day	_
25-22	4737-4738	,	_
25-23	4739-4742	3–4	_
25-24	4743-4748	times	_
25-25	4749-4752	per	_
25-26	4753-4757	week	_
25-27	4758-4759	,	_
25-28	4760-4763	1–2	_
25-29	4764-4769	times	_
25-30	4770-4773	per	_
25-31	4774-4778	week	_
25-32	4779-4780	,	_
25-33	4781-4785	once	_
25-34	4786-4789	per	_
25-35	4790-4795	month	_
25-36	4796-4797	,	_
25-37	4798-4802	6–11	_
25-38	4803-4808	times	_
25-39	4809-4812	per	_
25-40	4813-4817	year	_
25-41	4818-4819	,	_
25-42	4820-4823	1–5	_
25-43	4824-4829	times	_
25-44	4830-4833	per	_
25-45	4834-4838	year	_
25-46	4839-4840	,	_
25-47	4841-4843	no	_
25-48	4844-4847	use	_
25-49	4848-4849	)	_
25-50	4850-4851	.	_

Text=As in previous work from the MHCPD, our primary dosage estimate combined frequency and quantity measures (the product of average frequency and quantity) to create an average daily dose of cannabis (joints per day) for each assessment period.
26-1	4852-4854	As	_
26-2	4855-4857	in	_
26-3	4858-4866	previous	_
26-4	4867-4871	work	_
26-5	4872-4876	from	_
26-6	4877-4880	the	_
26-7	4881-4886	MHCPD	_
26-8	4887-4888	,	_
26-9	4889-4892	our	_
26-10	4893-4900	primary	_
26-11	4901-4907	dosage	_
26-12	4908-4916	estimate	_
26-13	4917-4925	combined	_
26-14	4926-4935	frequency	_
26-15	4936-4939	and	_
26-16	4940-4948	quantity	_
26-17	4949-4957	measures	_
26-18	4958-4959	(	_
26-19	4960-4963	the	_
26-20	4964-4971	product	_
26-21	4972-4974	of	_
26-22	4975-4982	average	_
26-23	4983-4992	frequency	_
26-24	4993-4996	and	_
26-25	4997-5005	quantity	_
26-26	5006-5007	)	_
26-27	5008-5010	to	_
26-28	5011-5017	create	_
26-29	5018-5020	an	_
26-30	5021-5028	average	_
26-31	5029-5034	daily	_
26-32	5035-5039	dose	_
26-33	5040-5042	of	_
26-34	5043-5051	cannabis	_
26-35	5052-5053	(	_
26-36	5054-5060	joints	_
26-37	5061-5064	per	_
26-38	5065-5068	day	_
26-39	5069-5070	)	_
26-40	5071-5074	for	_
26-41	5075-5079	each	_
26-42	5080-5090	assessment	_
26-43	5091-5097	period	_
26-44	5098-5099	.	_

Text=Based on age of onset and total cannabis use measures, subjects were distributed across three groups (Table 1): non-users (NU, n = 15), those who did not report cannabis use at any time point, cannabis experimenters (EXP, n = 14), those who reported an age of cannabis initiation but no other cannabis use, and repeated cannabis users (REP, n = 46), those who reported initiation and any additional cannabis use.
27-1	5100-5105	Based	_
27-2	5106-5108	on	_
27-3	5109-5112	age	_
27-4	5113-5115	of	_
27-5	5116-5121	onset	_
27-6	5122-5125	and	_
27-7	5126-5131	total	_
27-8	5132-5140	cannabis	_
27-9	5141-5144	use	_
27-10	5145-5153	measures	_
27-11	5154-5155	,	_
27-12	5156-5164	subjects	_
27-13	5165-5169	were	_
27-14	5170-5181	distributed	_
27-15	5182-5188	across	_
27-16	5189-5194	three	_
27-17	5195-5201	groups	_
27-18	5202-5203	(	_
27-19	5204-5209	Table	_
27-20	5210-5211	1	_
27-21	5212-5213	)	_
27-22	5214-5215	:	_
27-23	5216-5225	non-users	_
27-24	5226-5227	(	_
27-25	5228-5230	NU	_
27-26	5231-5232	,	_
27-27	5233-5234	n	_
27-28	5235-5236	=	_
27-29	5237-5239	15	_
27-30	5240-5241	)	_
27-31	5242-5243	,	_
27-32	5244-5249	those	_
27-33	5250-5253	who	_
27-34	5254-5257	did	_
27-35	5258-5261	not	_
27-36	5262-5268	report	_
27-37	5269-5277	cannabis	_
27-38	5278-5281	use	_
27-39	5282-5284	at	_
27-40	5285-5288	any	_
27-41	5289-5293	time	_
27-42	5294-5299	point	_
27-43	5300-5301	,	_
27-44	5302-5310	cannabis	_
27-45	5311-5324	experimenters	_
27-46	5325-5326	(	_
27-47	5327-5330	EXP	_
27-48	5331-5332	,	_
27-49	5333-5334	n	_
27-50	5335-5336	=	_
27-51	5337-5339	14	_
27-52	5340-5341	)	_
27-53	5342-5343	,	_
27-54	5344-5349	those	_
27-55	5350-5353	who	_
27-56	5354-5362	reported	_
27-57	5363-5365	an	_
27-58	5366-5369	age	_
27-59	5370-5372	of	_
27-60	5373-5381	cannabis	_
27-61	5382-5392	initiation	_
27-62	5393-5396	but	_
27-63	5397-5399	no	_
27-64	5400-5405	other	_
27-65	5406-5414	cannabis	_
27-66	5415-5418	use	_
27-67	5419-5420	,	_
27-68	5421-5424	and	_
27-69	5425-5433	repeated	_
27-70	5434-5442	cannabis	_
27-71	5443-5448	users	_
27-72	5449-5450	(	_
27-73	5451-5454	REP	_
27-74	5455-5456	,	_
27-75	5457-5458	n	_
27-76	5459-5460	=	_
27-77	5461-5463	46	_
27-78	5464-5465	)	_
27-79	5466-5467	,	_
27-80	5468-5473	those	_
27-81	5474-5477	who	_
27-82	5478-5486	reported	_
27-83	5487-5497	initiation	_
27-84	5498-5501	and	_
27-85	5502-5505	any	_
27-86	5506-5516	additional	_
27-87	5517-5525	cannabis	_
27-88	5526-5529	use	_
27-89	5530-5531	.	_

Text=No subjects reported use without age of initiation.
28-1	5532-5534	No	_
28-2	5535-5543	subjects	_
28-3	5544-5552	reported	_
28-4	5553-5556	use	_
28-5	5557-5564	without	_
28-6	5565-5568	age	_
28-7	5569-5571	of	_
28-8	5572-5582	initiation	_
28-9	5583-5584	.	_

Text=If subject report of cannabis age of onset differed between assessment periods, the cannabis age of onset from the earliest assessment period was used, as it was more proximal to the onset time.
29-1	5585-5587	If	_
29-2	5588-5595	subject	_
29-3	5596-5602	report	_
29-4	5603-5605	of	_
29-5	5606-5614	cannabis	_
29-6	5615-5618	age	_
29-7	5619-5621	of	_
29-8	5622-5627	onset	_
29-9	5628-5636	differed	_
29-10	5637-5644	between	_
29-11	5645-5655	assessment	_
29-12	5656-5663	periods	_
29-13	5664-5665	,	_
29-14	5666-5669	the	_
29-15	5670-5678	cannabis	_
29-16	5679-5682	age	_
29-17	5683-5685	of	_
29-18	5686-5691	onset	_
29-19	5692-5696	from	_
29-20	5697-5700	the	_
29-21	5701-5709	earliest	_
29-22	5710-5720	assessment	_
29-23	5721-5727	period	_
29-24	5728-5731	was	_
29-25	5732-5736	used	_
29-26	5737-5738	,	_
29-27	5739-5741	as	_
29-28	5742-5744	it	_
29-29	5745-5748	was	_
29-30	5749-5753	more	_
29-31	5754-5762	proximal	_
29-32	5763-5765	to	_
29-33	5766-5769	the	_
29-34	5770-5775	onset	_
29-35	5776-5780	time	_
29-36	5781-5782	.	_

Text=In statistical analysis, cannabis age of onset was examined as a continuous variable within both cannabis groups (EXP and REP).
30-1	5783-5785	In	_
30-2	5786-5797	statistical	_
30-3	5798-5806	analysis	_
30-4	5807-5808	,	_
30-5	5809-5817	cannabis	_
30-6	5818-5821	age	_
30-7	5822-5824	of	_
30-8	5825-5830	onset	_
30-9	5831-5834	was	_
30-10	5835-5843	examined	_
30-11	5844-5846	as	_
30-12	5847-5848	a	_
30-13	5849-5859	continuous	_
30-14	5860-5868	variable	_
30-15	5869-5875	within	_
30-16	5876-5880	both	_
30-17	5881-5889	cannabis	_
30-18	5890-5896	groups	_
30-19	5897-5898	(	_
30-20	5899-5902	EXP	_
30-21	5903-5906	and	_
30-22	5907-5910	REP	_
30-23	5911-5912	)	_
30-24	5913-5914	.	_

Text=Total cannabis use, measured as the sum of joints per day across assessments (14-, 16-, 22-, 28-years-old) and conceptualized as a general measure of cannabis use severity, was examined only in those with a reported cannabis dose (REP).
31-1	5915-5920	Total	_
31-2	5921-5929	cannabis	_
31-3	5930-5933	use	_
31-4	5934-5935	,	_
31-5	5936-5944	measured	_
31-6	5945-5947	as	_
31-7	5948-5951	the	_
31-8	5952-5955	sum	_
31-9	5956-5958	of	_
31-10	5959-5965	joints	_
31-11	5966-5969	per	_
31-12	5970-5973	day	_
31-13	5974-5980	across	_
31-14	5981-5992	assessments	_
31-15	5993-5994	(	_
31-16	5995-5998	14-	_
31-17	5999-6000	,	_
31-18	6001-6004	16-	_
31-19	6005-6006	,	_
31-20	6007-6010	22-	_
31-21	6011-6012	,	_
31-22	6013-6025	28-years-old	_
31-23	6026-6027	)	_
31-24	6028-6031	and	_
31-25	6032-6046	conceptualized	_
31-26	6047-6049	as	_
31-27	6050-6051	a	_
31-28	6052-6059	general	_
31-29	6060-6067	measure	_
31-30	6068-6070	of	_
31-31	6071-6079	cannabis	_
31-32	6080-6083	use	_
31-33	6084-6092	severity	_
31-34	6093-6094	,	_
31-35	6095-6098	was	_
31-36	6099-6107	examined	_
31-37	6108-6112	only	_
31-38	6113-6115	in	_
31-39	6116-6121	those	_
31-40	6122-6126	with	_
31-41	6127-6128	a	_
31-42	6129-6137	reported	_
31-43	6138-6146	cannabis	_
31-44	6147-6151	dose	_
31-45	6152-6153	(	_
31-46	6154-6157	REP	_
31-47	6158-6159	)	_
31-48	6160-6161	.	_

Text=Total cannabis use measures were log transformed to reduce the impact of the few high dose participants, evident in the strong positive skew of the total cannabis use distribution (Supplemental Fig.
32-1	6162-6167	Total	_
32-2	6168-6176	cannabis	_
32-3	6177-6180	use	_
32-4	6181-6189	measures	_
32-5	6190-6194	were	_
32-6	6195-6198	log	_
32-7	6199-6210	transformed	_
32-8	6211-6213	to	_
32-9	6214-6220	reduce	_
32-10	6221-6224	the	_
32-11	6225-6231	impact	_
32-12	6232-6234	of	_
32-13	6235-6238	the	_
32-14	6239-6242	few	_
32-15	6243-6247	high	_
32-16	6248-6252	dose	_
32-17	6253-6265	participants	_
32-18	6266-6267	,	_
32-19	6268-6275	evident	_
32-20	6276-6278	in	_
32-21	6279-6282	the	_
32-22	6283-6289	strong	_
32-23	6290-6298	positive	_
32-24	6299-6303	skew	_
32-25	6304-6306	of	_
32-26	6307-6310	the	_
32-27	6311-6316	total	_
32-28	6317-6325	cannabis	_
32-29	6326-6329	use	_
32-30	6330-6342	distribution	_
32-31	6343-6344	(	_
32-32	6345-6357	Supplemental	_
32-33	6358-6361	Fig	_
32-34	6362-6363	.	_

Text=S1).
33-1	6364-6366	S1	_
33-2	6367-6368	)	_
33-3	6369-6370	.	_

Text=On the day of testing, all subjects included in the current analysis (N = 75) denied recreational drug use of any kind during the past week and had a negative multi-drug urine screen (Uritox Medical, Toledo, OH, THC Threshold 50 ng/ml).
34-1	6371-6373	On	_
34-2	6374-6377	the	_
34-3	6378-6381	day	_
34-4	6382-6384	of	_
34-5	6385-6392	testing	_
34-6	6393-6394	,	_
34-7	6395-6398	all	_
34-8	6399-6407	subjects	_
34-9	6408-6416	included	_
34-10	6417-6419	in	_
34-11	6420-6423	the	_
34-12	6424-6431	current	_
34-13	6432-6440	analysis	_
34-14	6441-6442	(	_
34-15	6443-6444	N	_
34-16	6445-6446	=	_
34-17	6447-6449	75	_
34-18	6450-6451	)	_
34-19	6452-6458	denied	_
34-20	6459-6471	recreational	_
34-21	6472-6476	drug	_
34-22	6477-6480	use	_
34-23	6481-6483	of	_
34-24	6484-6487	any	_
34-25	6488-6492	kind	_
34-26	6493-6499	during	_
34-27	6500-6503	the	_
34-28	6504-6508	past	_
34-29	6509-6513	week	_
34-30	6514-6517	and	_
34-31	6518-6521	had	_
34-32	6522-6523	a	_
34-33	6524-6532	negative	_
34-34	6533-6543	multi-drug	_
34-35	6544-6549	urine	_
34-36	6550-6556	screen	_
34-37	6557-6558	(	_
34-38	6559-6565	Uritox	_
34-39	6566-6573	Medical	_
34-40	6574-6575	,	_
34-41	6576-6582	Toledo	_
34-42	6583-6584	,	_
34-43	6585-6587	OH	_
34-44	6588-6589	,	_
34-45	6590-6593	THC	_
34-46	6594-6603	Threshold	_
34-47	6604-6606	50	_
34-48	6607-6612	ng/ml	_
34-49	6613-6614	)	_
34-50	6615-6616	.	_

Text=Accordingly, we consider all subjects abstinent at testing (no recent use).
35-1	6617-6628	Accordingly	_
35-2	6629-6630	,	_
35-3	6631-6633	we	_
35-4	6634-6642	consider	_
35-5	6643-6646	all	_
35-6	6647-6655	subjects	_
35-7	6656-6665	abstinent	_
35-8	6666-6668	at	_
35-9	6669-6676	testing	_
35-10	6677-6678	(	_
35-11	6679-6681	no	_
35-12	6682-6688	recent	_
35-13	6689-6692	use	_
35-14	6693-6694	)	_
35-15	6695-6696	.	_

Text=Demographics and participant characteristics As detailed in previous work, extensive participant demographics and characteristics were collected as part of MHCPD assessments.
36-1	6697-6709	Demographics	_
36-2	6710-6713	and	_
36-3	6714-6725	participant	_
36-4	6726-6741	characteristics	_
36-5	6742-6744	As	_
36-6	6745-6753	detailed	_
36-7	6754-6756	in	_
36-8	6757-6765	previous	_
36-9	6766-6770	work	_
36-10	6771-6772	,	_
36-11	6773-6782	extensive	_
36-12	6783-6794	participant	_
36-13	6795-6807	demographics	_
36-14	6808-6811	and	_
36-15	6812-6827	characteristics	_
36-16	6828-6832	were	_
36-17	6833-6842	collected	_
36-18	6843-6845	as	_
36-19	6846-6850	part	_
36-20	6851-6853	of	_
36-21	6854-6859	MHCPD	_
36-22	6860-6871	assessments	_
36-23	6872-6873	.	_

Text=In the current work, we included measures associated with cannabis use risk in previous work in the MHCPD (e.g.,) and other studies of adolescent cannabis use (e.g.,) (see Table 1).
37-1	6874-6876	In	_
37-2	6877-6880	the	_
37-3	6881-6888	current	_
37-4	6889-6893	work	_
37-5	6894-6895	,	_
37-6	6896-6898	we	_
37-7	6899-6907	included	_
37-8	6908-6916	measures	_
37-9	6917-6927	associated	_
37-10	6928-6932	with	_
37-11	6933-6941	cannabis	_
37-12	6942-6945	use	_
37-13	6946-6950	risk	_
37-14	6951-6953	in	_
37-15	6954-6962	previous	_
37-16	6963-6967	work	_
37-17	6968-6970	in	_
37-18	6971-6974	the	_
37-19	6975-6980	MHCPD	_
37-20	6981-6982	(	_
37-21	6983-6987	e.g.	_
37-22	6988-6989	,	_
37-23	6990-6991	)	_
37-24	6992-6995	and	_
37-25	6996-7001	other	_
37-26	7002-7009	studies	_
37-27	7010-7012	of	_
37-28	7013-7023	adolescent	_
37-29	7024-7032	cannabis	_
37-30	7033-7036	use	_
37-31	7037-7038	(	_
37-32	7039-7043	e.g.	_
37-33	7044-7045	,	_
37-34	7046-7047	)	_
37-35	7048-7049	(	_
37-36	7050-7053	see	_
37-37	7054-7059	Table	_
37-38	7060-7061	1	_
37-39	7062-7063	)	_
37-40	7064-7065	.	_

Text=Measures examined as potential covariates included socioeconomic status (highest level of education, family income), IQ (WISC-III Full Scale), other substance use (alcohol and cigarette use), and prenatal drug exposure (cannabis, alcohol, and cigarette).
38-1	7066-7074	Measures	_
38-2	7075-7083	examined	_
38-3	7084-7086	as	_
38-4	7087-7096	potential	_
38-5	7097-7107	covariates	_
38-6	7108-7116	included	_
38-7	7117-7130	socioeconomic	_
38-8	7131-7137	status	_
38-9	7138-7139	(	_
38-10	7140-7147	highest	_
38-11	7148-7153	level	_
38-12	7154-7156	of	_
38-13	7157-7166	education	_
38-14	7167-7168	,	_
38-15	7169-7175	family	_
38-16	7176-7182	income	_
38-17	7183-7184	)	_
38-18	7185-7186	,	_
38-19	7187-7189	IQ	_
38-20	7190-7191	(	_
38-21	7192-7200	WISC-III	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
38-22	7201-7205	Full	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
38-23	7206-7211	Scale	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
38-24	7212-7213	)	_
38-25	7214-7215	,	_
38-26	7216-7221	other	_
38-27	7222-7231	substance	_
38-28	7232-7235	use	_
38-29	7236-7237	(	_
38-30	7238-7245	alcohol	_
38-31	7246-7249	and	_
38-32	7250-7259	cigarette	_
38-33	7260-7263	use	_
38-34	7264-7265	)	_
38-35	7266-7267	,	_
38-36	7268-7271	and	_
38-37	7272-7280	prenatal	_
38-38	7281-7285	drug	_
38-39	7286-7294	exposure	_
38-40	7295-7296	(	_
38-41	7297-7305	cannabis	_
38-42	7306-7307	,	_
38-43	7308-7315	alcohol	_
38-44	7316-7317	,	_
38-45	7318-7321	and	_
38-46	7322-7331	cigarette	_
38-47	7332-7333	)	_
38-48	7334-7335	.	_

Text=In cases where measures were available from multiple assessment phases (e.g., IQ, family income), we selected the measure that was closest to the year of neuroimaging testing (age 28).
39-1	7336-7338	In	_
39-2	7339-7344	cases	_
39-3	7345-7350	where	_
39-4	7351-7359	measures	_
39-5	7360-7364	were	_
39-6	7365-7374	available	_
39-7	7375-7379	from	_
39-8	7380-7388	multiple	_
39-9	7389-7399	assessment	_
39-10	7400-7406	phases	_
39-11	7407-7408	(	_
39-12	7409-7413	e.g.	_
39-13	7414-7415	,	_
39-14	7416-7418	IQ	_
39-15	7419-7420	,	_
39-16	7421-7427	family	_
39-17	7428-7434	income	_
39-18	7435-7436	)	_
39-19	7437-7438	,	_
39-20	7439-7441	we	_
39-21	7442-7450	selected	_
39-22	7451-7454	the	_
39-23	7455-7462	measure	_
39-24	7463-7467	that	_
39-25	7468-7471	was	_
39-26	7472-7479	closest	_
39-27	7480-7482	to	_
39-28	7483-7486	the	_
39-29	7487-7491	year	_
39-30	7492-7494	of	_
39-31	7495-7507	neuroimaging	_
39-32	7508-7515	testing	_
39-33	7516-7517	(	_
39-34	7518-7521	age	_
39-35	7522-7524	28	_
39-36	7525-7526	)	_
39-37	7527-7528	.	_

Text=For five subjects, the most recent IQ measurement (age 14) was missing but age 10 IQ scores were available for these subjects.
40-1	7529-7532	For	_
40-2	7533-7537	five	_
40-3	7538-7546	subjects	_
40-4	7547-7548	,	_
40-5	7549-7552	the	_
40-6	7553-7557	most	_
40-7	7558-7564	recent	_
40-8	7565-7567	IQ	_
40-9	7568-7579	measurement	_
40-10	7580-7581	(	_
40-11	7582-7585	age	_
40-12	7586-7588	14	_
40-13	7589-7590	)	_
40-14	7591-7594	was	_
40-15	7595-7602	missing	_
40-16	7603-7606	but	_
40-17	7607-7610	age	_
40-18	7611-7613	10	_
40-19	7614-7616	IQ	_
40-20	7617-7623	scores	_
40-21	7624-7628	were	_
40-22	7629-7638	available	_
40-23	7639-7642	for	_
40-24	7643-7648	these	_
40-25	7649-7657	subjects	_
40-26	7658-7659	.	_

Text=Similarly, for seven subjects, the most recent family income data (age 16) were missing but age 10 family income data was available for these subjects.
41-1	7660-7669	Similarly	_
41-2	7670-7671	,	_
41-3	7672-7675	for	_
41-4	7676-7681	seven	_
41-5	7682-7690	subjects	_
41-6	7691-7692	,	_
41-7	7693-7696	the	_
41-8	7697-7701	most	_
41-9	7702-7708	recent	_
41-10	7709-7715	family	_
41-11	7716-7722	income	_
41-12	7723-7727	data	_
41-13	7728-7729	(	_
41-14	7730-7733	age	_
41-15	7734-7736	16	_
41-16	7737-7738	)	_
41-17	7739-7743	were	_
41-18	7744-7751	missing	_
41-19	7752-7755	but	_
41-20	7756-7759	age	_
41-21	7760-7762	10	_
41-22	7763-7769	family	_
41-23	7770-7776	income	_
41-24	7777-7781	data	_
41-25	7782-7785	was	_
41-26	7786-7795	available	_
41-27	7796-7799	for	_
41-28	7800-7805	these	_
41-29	7806-7814	subjects	_
41-30	7815-7816	.	_

Text=In both cases, data from these earlier assessments were included and adjusted based on regression models predicting the most recent assessment from the rest of the cohort and used in covariate models (IQ, Standford-Binet Intelligence Scale 4th Edition age 10 predicting WISC at age 14, B = .986, t = 8.87, p <.0001; family income at age 10 predicting family income at age 16 (n = 7), B = .848, t = 8.68, p <.0001).
42-1	7817-7819	In	_
42-2	7820-7824	both	_
42-3	7825-7830	cases	_
42-4	7831-7832	,	_
42-5	7833-7837	data	_
42-6	7838-7842	from	_
42-7	7843-7848	these	_
42-8	7849-7856	earlier	_
42-9	7857-7868	assessments	_
42-10	7869-7873	were	_
42-11	7874-7882	included	_
42-12	7883-7886	and	_
42-13	7887-7895	adjusted	_
42-14	7896-7901	based	_
42-15	7902-7904	on	_
42-16	7905-7915	regression	_
42-17	7916-7922	models	_
42-18	7923-7933	predicting	_
42-19	7934-7937	the	_
42-20	7938-7942	most	_
42-21	7943-7949	recent	_
42-22	7950-7960	assessment	_
42-23	7961-7965	from	_
42-24	7966-7969	the	_
42-25	7970-7974	rest	_
42-26	7975-7977	of	_
42-27	7978-7981	the	_
42-28	7982-7988	cohort	_
42-29	7989-7992	and	_
42-30	7993-7997	used	_
42-31	7998-8000	in	_
42-32	8001-8010	covariate	_
42-33	8011-8017	models	_
42-34	8018-8019	(	_
42-35	8020-8022	IQ	_
42-36	8023-8024	,	_
42-37	8025-8040	Standford-Binet	_
42-38	8041-8053	Intelligence	_
42-39	8054-8059	Scale	_
42-40	8060-8063	4th	_
42-41	8064-8071	Edition	_
42-42	8072-8075	age	_
42-43	8076-8078	10	_
42-44	8079-8089	predicting	_
42-45	8090-8094	WISC	_
42-46	8095-8097	at	_
42-47	8098-8101	age	_
42-48	8102-8104	14	_
42-49	8105-8106	,	_
42-50	8107-8108	B	_
42-51	8109-8110	=	_
42-52	8111-8115	.986	_
42-53	8116-8117	,	_
42-54	8118-8119	t	_
42-55	8120-8121	=	_
42-56	8122-8126	8.87	_
42-57	8127-8128	,	_
42-58	8129-8130	p	_
42-59	8131-8132	<	_
42-60	8133-8138	.0001	_
42-61	8139-8140	;	_
42-62	8141-8147	family	_
42-63	8148-8154	income	_
42-64	8155-8157	at	_
42-65	8158-8161	age	_
42-66	8162-8164	10	_
42-67	8165-8175	predicting	_
42-68	8176-8182	family	_
42-69	8183-8189	income	_
42-70	8190-8192	at	_
42-71	8193-8196	age	_
42-72	8197-8199	16	_
42-73	8200-8201	(	_
42-74	8202-8203	n	_
42-75	8204-8205	=	_
42-76	8206-8207	7	_
42-77	8208-8209	)	_
42-78	8210-8211	,	_
42-79	8212-8213	B	_
42-80	8214-8215	=	_
42-81	8216-8220	.848	_
42-82	8221-8222	,	_
42-83	8223-8224	t	_
42-84	8225-8226	=	_
42-85	8227-8231	8.68	_
42-86	8232-8233	,	_
42-87	8234-8235	p	_
42-88	8236-8237	<	_
42-89	8238-8243	.0001	_
42-90	8244-8245	)	_
42-91	8246-8247	.	_

Text=fMRI task design Across four fMRI runs, participants performed 96 full trials of a Sternberg type spatial working memory task (see Fig.
43-1	8248-8252	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
43-2	8253-8257	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
43-3	8258-8264	design	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
43-4	8265-8271	Across	_
43-5	8272-8276	four	_
43-6	8277-8281	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
43-7	8282-8286	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
43-8	8287-8288	,	_
43-9	8289-8301	participants	_
43-10	8302-8311	performed	_
43-11	8312-8314	96	_
43-12	8315-8319	full	_
43-13	8320-8326	trials	_
43-14	8327-8329	of	_
43-15	8330-8331	a	_
43-16	8332-8341	Sternberg	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
43-17	8342-8346	type	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
43-18	8347-8354	spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
43-19	8355-8362	working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
43-20	8363-8369	memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
43-21	8370-8374	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
43-22	8375-8376	(	_
43-23	8377-8380	see	_
43-24	8381-8384	Fig	_
43-25	8385-8386	.	_

Text=1) with a 2 (load) x 2 (delay length) x 2 (cue validity) factorial design.
44-1	8387-8388	1	_
44-2	8389-8390	)	_
44-3	8391-8395	with	_
44-4	8396-8397	a	_
44-5	8398-8399	2	_
44-6	8400-8401	(	_
44-7	8402-8406	load	_
44-8	8407-8408	)	_
44-9	8409-8410	x	_
44-10	8411-8412	2	_
44-11	8413-8414	(	_
44-12	8415-8420	delay	_
44-13	8421-8427	length	_
44-14	8428-8429	)	_
44-15	8430-8431	x	_
44-16	8432-8433	2	_
44-17	8434-8435	(	_
44-18	8436-8439	cue	_
44-19	8440-8448	validity	_
44-20	8449-8450	)	_
44-21	8451-8460	factorial	_
44-22	8461-8467	design	_
44-23	8468-8469	.	_

Text=The task included three epochs: a cue (encoding) epoch (1.5s) where subjects were shown to-be-remembered stimuli (one or three spatial locations), a delay (maintenance) epoch, where subjects maintained information (1.5 or 6s), and a target (retrieval) epoch, where subjects had to retrieve information and respond to whether a probe (four spatial locations) matched any of the cued information (<3s).
45-1	8470-8473	The	_
45-2	8474-8478	task	_
45-3	8479-8487	included	_
45-4	8488-8493	three	_
45-5	8494-8500	epochs	_
45-6	8501-8502	:	_
45-7	8503-8504	a	_
45-8	8505-8508	cue	_
45-9	8509-8510	(	_
45-10	8511-8519	encoding	_
45-11	8520-8521	)	_
45-12	8522-8527	epoch	_
45-13	8528-8529	(	_
45-14	8530-8534	1.5s	_
45-15	8535-8536	)	_
45-16	8537-8542	where	_
45-17	8543-8551	subjects	_
45-18	8552-8556	were	_
45-19	8557-8562	shown	_
45-20	8563-8579	to-be-remembered	_
45-21	8580-8587	stimuli	_
45-22	8588-8589	(	_
45-23	8590-8593	one	_
45-24	8594-8596	or	_
45-25	8597-8602	three	_
45-26	8603-8610	spatial	_
45-27	8611-8620	locations	_
45-28	8621-8622	)	_
45-29	8623-8624	,	_
45-30	8625-8626	a	_
45-31	8627-8632	delay	_
45-32	8633-8634	(	_
45-33	8635-8646	maintenance	_
45-34	8647-8648	)	_
45-35	8649-8654	epoch	_
45-36	8655-8656	,	_
45-37	8657-8662	where	_
45-38	8663-8671	subjects	_
45-39	8672-8682	maintained	_
45-40	8683-8694	information	_
45-41	8695-8696	(	_
45-42	8697-8700	1.5	_
45-43	8701-8703	or	_
45-44	8704-8706	6s	_
45-45	8707-8708	)	_
45-46	8709-8710	,	_
45-47	8711-8714	and	_
45-48	8715-8716	a	_
45-49	8717-8723	target	_
45-50	8724-8725	(	_
45-51	8726-8735	retrieval	_
45-52	8736-8737	)	_
45-53	8738-8743	epoch	_
45-54	8744-8745	,	_
45-55	8746-8751	where	_
45-56	8752-8760	subjects	_
45-57	8761-8764	had	_
45-58	8765-8767	to	_
45-59	8768-8776	retrieve	_
45-60	8777-8788	information	_
45-61	8789-8792	and	_
45-62	8793-8800	respond	_
45-63	8801-8803	to	_
45-64	8804-8811	whether	_
45-65	8812-8813	a	_
45-66	8814-8819	probe	_
45-67	8820-8821	(	_
45-68	8822-8826	four	_
45-69	8827-8834	spatial	_
45-70	8835-8844	locations	_
45-71	8845-8846	)	_
45-72	8847-8854	matched	_
45-73	8855-8858	any	_
45-74	8859-8861	of	_
45-75	8862-8865	the	_
45-76	8866-8870	cued	_
45-77	8871-8882	information	_
45-78	8883-8884	(	_
45-79	8885-8886	<	_
45-80	8887-8889	3s	_
45-81	8890-8891	)	_
45-82	8892-8893	.	_

Text=An additional 48 partial trials with either the cue epoch alone (n = 24) or the cue and delay epochs but not the target epoch (n = 24) were included in order to estimate the hemodynamic response for each epoch.
46-1	8894-8896	An	_
46-2	8897-8907	additional	_
46-3	8908-8910	48	_
46-4	8911-8918	partial	_
46-5	8919-8925	trials	_
46-6	8926-8930	with	_
46-7	8931-8937	either	_
46-8	8938-8941	the	_
46-9	8942-8945	cue	_
46-10	8946-8951	epoch	_
46-11	8952-8957	alone	_
46-12	8958-8959	(	_
46-13	8960-8961	n	_
46-14	8962-8963	=	_
46-15	8964-8966	24	_
46-16	8967-8968	)	_
46-17	8969-8971	or	_
46-18	8972-8975	the	_
46-19	8976-8979	cue	_
46-20	8980-8983	and	_
46-21	8984-8989	delay	_
46-22	8990-8996	epochs	_
46-23	8997-9000	but	_
46-24	9001-9004	not	_
46-25	9005-9008	the	_
46-26	9009-9015	target	_
46-27	9016-9021	epoch	_
46-28	9022-9023	(	_
46-29	9024-9025	n	_
46-30	9026-9027	=	_
46-31	9028-9030	24	_
46-32	9031-9032	)	_
46-33	9033-9037	were	_
46-34	9038-9046	included	_
46-35	9047-9049	in	_
46-36	9050-9055	order	_
46-37	9056-9058	to	_
46-38	9059-9067	estimate	_
46-39	9068-9071	the	_
46-40	9072-9083	hemodynamic	_
46-41	9084-9092	response	_
46-42	9093-9096	for	_
46-43	9097-9101	each	_
46-44	9102-9107	epoch	_
46-45	9108-9109	.	_

Text=The task utilized a mixed block/event-related fMRI design with interleaved task blocks (102s) and fixation only periods (12s).
47-1	9110-9113	The	_
47-2	9114-9118	task	_
47-3	9119-9127	utilized	_
47-4	9128-9129	a	_
47-5	9130-9135	mixed	_
47-6	9136-9155	block/event-related	_
47-7	9156-9160	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
47-8	9161-9167	design	_
47-9	9168-9172	with	_
47-10	9173-9184	interleaved	_
47-11	9185-9189	task	_
47-12	9190-9196	blocks	_
47-13	9197-9198	(	_
47-14	9199-9203	102s	_
47-15	9204-9205	)	_
47-16	9206-9209	and	_
47-17	9210-9218	fixation	_
47-18	9219-9223	only	_
47-19	9224-9231	periods	_
47-20	9232-9233	(	_
47-21	9234-9237	12s	_
47-22	9238-9239	)	_
47-23	9240-9241	.	_

Text=Inter-trial intervals within task blocks were pseudo-randomized and ranged from 1.5s to 5.5s.
48-1	9242-9253	Inter-trial	_
48-2	9254-9263	intervals	_
48-3	9264-9270	within	_
48-4	9271-9275	task	_
48-5	9276-9282	blocks	_
48-6	9283-9287	were	_
48-7	9288-9305	pseudo-randomized	_
48-8	9306-9309	and	_
48-9	9310-9316	ranged	_
48-10	9317-9321	from	_
48-11	9322-9326	1.5s	_
48-12	9327-9329	to	_
48-13	9330-9334	5.5s	_
48-14	9335-9336	.	_

Text=fMRI data acquisition Stimuli were presented onto a screen behind the scanner using E- Prime software (Psychology Software Tools, Inc., Pittsburgh, PA) and were visible to the subject through a mirror mounted to the head coil.
49-1	9337-9341	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-2	9342-9346	data	_
49-3	9347-9358	acquisition	_
49-4	9359-9366	Stimuli	_
49-5	9367-9371	were	_
49-6	9372-9381	presented	_
49-7	9382-9386	onto	_
49-8	9387-9388	a	_
49-9	9389-9395	screen	_
49-10	9396-9402	behind	_
49-11	9403-9406	the	_
49-12	9407-9414	scanner	_
49-13	9415-9420	using	_
49-14	9421-9423	E-	_
49-15	9424-9429	Prime	_
49-16	9430-9438	software	_
49-17	9439-9440	(	_
49-18	9441-9451	Psychology	_
49-19	9452-9460	Software	_
49-20	9461-9466	Tools	_
49-21	9467-9468	,	_
49-22	9469-9473	Inc.	_
49-23	9474-9475	,	_
49-24	9476-9486	Pittsburgh	_
49-25	9487-9488	,	_
49-26	9489-9491	PA	_
49-27	9492-9493	)	_
49-28	9494-9497	and	_
49-29	9498-9502	were	_
49-30	9503-9510	visible	_
49-31	9511-9513	to	_
49-32	9514-9517	the	_
49-33	9518-9525	subject	_
49-34	9526-9533	through	_
49-35	9534-9535	a	_
49-36	9536-9542	mirror	_
49-37	9543-9550	mounted	_
49-38	9551-9553	to	_
49-39	9554-9557	the	_
49-40	9558-9562	head	_
49-41	9563-9567	coil	_
49-42	9568-9569	.	_

Text=Reaction time in the working memory task was recorded as the time in milliseconds from the probe display (four yellow circles) to response (button press on MRI safe button box).
50-1	9570-9578	Reaction	_
50-2	9579-9583	time	_
50-3	9584-9586	in	_
50-4	9587-9590	the	_
50-5	9591-9598	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
50-6	9599-9605	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
50-7	9606-9610	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
50-8	9611-9614	was	_
50-9	9615-9623	recorded	_
50-10	9624-9626	as	_
50-11	9627-9630	the	_
50-12	9631-9635	time	_
50-13	9636-9638	in	_
50-14	9639-9651	milliseconds	_
50-15	9652-9656	from	_
50-16	9657-9660	the	_
50-17	9661-9666	probe	_
50-18	9667-9674	display	_
50-19	9675-9676	(	_
50-20	9677-9681	four	_
50-21	9682-9688	yellow	_
50-22	9689-9696	circles	_
50-23	9697-9698	)	_
50-24	9699-9701	to	_
50-25	9702-9710	response	_
50-26	9711-9712	(	_
50-27	9713-9719	button	_
50-28	9720-9725	press	_
50-29	9726-9728	on	_
50-30	9729-9732	MRI	_
50-31	9733-9737	safe	_
50-32	9738-9744	button	_
50-33	9745-9748	box	_
50-34	9749-9750	)	_
50-35	9751-9752	.	_

Text=Trials were marked correct if the button response (Pointer Finger = yes/match; Middle Finger = no/no match; right hand glove) correctly indicated whether or not one of the probes occupied a previously cued location.
51-1	9753-9759	Trials	_
51-2	9760-9764	were	_
51-3	9765-9771	marked	_
51-4	9772-9779	correct	_
51-5	9780-9782	if	_
51-6	9783-9786	the	_
51-7	9787-9793	button	_
51-8	9794-9802	response	_
51-9	9803-9804	(	_
51-10	9805-9812	Pointer	_
51-11	9813-9819	Finger	_
51-12	9820-9821	=	_
51-13	9822-9831	yes/match	_
51-14	9832-9833	;	_
51-15	9834-9840	Middle	_
51-16	9841-9847	Finger	_
51-17	9848-9849	=	_
51-18	9850-9855	no/no	_
51-19	9856-9861	match	_
51-20	9862-9863	;	_
51-21	9864-9869	right	_
51-22	9870-9874	hand	_
51-23	9875-9880	glove	_
51-24	9881-9882	)	_
51-25	9883-9892	correctly	_
51-26	9893-9902	indicated	_
51-27	9903-9910	whether	_
51-28	9911-9913	or	_
51-29	9914-9917	not	_
51-30	9918-9921	one	_
51-31	9922-9924	of	_
51-32	9925-9928	the	_
51-33	9929-9935	probes	_
51-34	9936-9944	occupied	_
51-35	9945-9946	a	_
51-36	9947-9957	previously	_
51-37	9958-9962	cued	_
51-38	9963-9971	location	_
51-39	9972-9973	.	_

Text=If no response was given after 3000 ms, the trial was “ timed-out ” and marked as an omission error.
52-1	9974-9976	If	_
52-2	9977-9979	no	_
52-3	9980-9988	response	_
52-4	9989-9992	was	_
52-5	9993-9998	given	_
52-6	9999-10004	after	_
52-7	10005-10009	3000	_
52-8	10010-10012	ms	_
52-9	10013-10014	,	_
52-10	10015-10018	the	_
52-11	10019-10024	trial	_
52-12	10025-10028	was	_
52-13	10029-10030	“	_
52-14	10031-10040	timed-out	_
52-15	10041-10042	”	_
52-16	10043-10046	and	_
52-17	10047-10053	marked	_
52-18	10054-10056	as	_
52-19	10057-10059	an	_
52-20	10060-10068	omission	_
52-21	10069-10074	error	_
52-22	10075-10076	.	_

Text=Imaging data were collected using a 3.0-T Siemens Magnetom TIM Trio (Erlangen, Germany) at the Magnetic Resonance Research Center at the University of Pittsburgh.
53-1	10077-10084	Imaging	_
53-2	10085-10089	data	_
53-3	10090-10094	were	_
53-4	10095-10104	collected	_
53-5	10105-10110	using	_
53-6	10111-10112	a	_
53-7	10113-10118	3.0-T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
53-8	10119-10126	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
53-9	10127-10135	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
53-10	10136-10139	TIM	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
53-11	10140-10144	Trio	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
53-12	10145-10146	(	_
53-13	10147-10155	Erlangen	_
53-14	10156-10157	,	_
53-15	10158-10165	Germany	_
53-16	10166-10167	)	_
53-17	10168-10170	at	_
53-18	10171-10174	the	_
53-19	10175-10183	Magnetic	_
53-20	10184-10193	Resonance	_
53-21	10194-10202	Research	_
53-22	10203-10209	Center	_
53-23	10210-10212	at	_
53-24	10213-10216	the	_
53-25	10217-10227	University	_
53-26	10228-10230	of	_
53-27	10231-10241	Pittsburgh	_
53-28	10242-10243	.	_

Text=Structural images were collected using a magnetization prepared rapid acquistion gradient-echo (MP-rage) pulse sequence with a 192 slices (1 mm slice thickness; 1 mm isotropic voxels).
54-1	10244-10254	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
54-2	10255-10261	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
54-3	10262-10266	were	_
54-4	10267-10276	collected	_
54-5	10277-10282	using	_
54-6	10283-10284	a	_
54-7	10285-10298	magnetization	_
54-8	10299-10307	prepared	_
54-9	10308-10313	rapid	_
54-10	10314-10324	acquistion	_
54-11	10325-10338	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
54-12	10339-10340	(	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
54-13	10341-10348	MP-rage	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
54-14	10349-10350	)	http://maven.renci.org/NeuroBridge/neurobridge#Radiograph
54-15	10351-10356	pulse	_
54-16	10357-10365	sequence	_
54-17	10366-10370	with	_
54-18	10371-10372	a	_
54-19	10373-10376	192	_
54-20	10377-10383	slices	_
54-21	10384-10385	(	_
54-22	10386-10387	1	_
54-23	10388-10390	mm	_
54-24	10391-10396	slice	_
54-25	10397-10406	thickness	_
54-26	10407-10408	;	_
54-27	10409-10410	1	_
54-28	10411-10413	mm	_
54-29	10414-10423	isotropic	_
54-30	10424-10430	voxels	_
54-31	10431-10432	)	_
54-32	10433-10434	.	_

Text=Functional data were collected using an echo-planar imaging (EPI) sequence with the following parameters: TR = 2.0s, TE = 20ms, Flip Angle = 80°, and 128 × 120 acquisition matrix with a field of view of 220 mm.
55-1	10435-10445	Functional	_
55-2	10446-10450	data	_
55-3	10451-10455	were	_
55-4	10456-10465	collected	_
55-5	10466-10471	using	_
55-6	10472-10474	an	_
55-7	10475-10486	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-8	10487-10494	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-9	10495-10496	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-10	10497-10500	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-11	10501-10502	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-12	10503-10511	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-13	10512-10516	with	_
55-14	10517-10520	the	_
55-15	10521-10530	following	_
55-16	10531-10541	parameters	_
55-17	10542-10543	:	_
55-18	10544-10546	TR	_
55-19	10547-10548	=	_
55-20	10549-10553	2.0s	_
55-21	10554-10555	,	_
55-22	10556-10558	TE	_
55-23	10559-10560	=	_
55-24	10561-10565	20ms	_
55-25	10566-10567	,	_
55-26	10568-10572	Flip	_
55-27	10573-10578	Angle	_
55-28	10579-10580	=	_
55-29	10581-10584	80°	_
55-30	10585-10586	,	_
55-31	10587-10590	and	_
55-32	10591-10594	128	_
55-33	10595-10596	×	_
55-34	10597-10600	120	_
55-35	10601-10612	acquisition	_
55-36	10613-10619	matrix	_
55-37	10620-10624	with	_
55-38	10625-10626	a	_
55-39	10627-10632	field	_
55-40	10633-10635	of	_
55-41	10636-10640	view	_
55-42	10641-10643	of	_
55-43	10644-10647	220	_
55-44	10648-10650	mm	_
55-45	10651-10652	.	_

Text=Thirty-three slices were collected in the axial plane with an anisotropic voxel size of 1.72 mm × 1.72 mm × 3 mm and a .75 mm gap between slices.
56-1	10653-10665	Thirty-three	_
56-2	10666-10672	slices	_
56-3	10673-10677	were	_
56-4	10678-10687	collected	_
56-5	10688-10690	in	_
56-6	10691-10694	the	_
56-7	10695-10700	axial	_
56-8	10701-10706	plane	_
56-9	10707-10711	with	_
56-10	10712-10714	an	_
56-11	10715-10726	anisotropic	_
56-12	10727-10732	voxel	_
56-13	10733-10737	size	_
56-14	10738-10740	of	_
56-15	10741-10745	1.72	_
56-16	10746-10748	mm	_
56-17	10749-10750	×	_
56-18	10751-10755	1.72	_
56-19	10756-10758	mm	_
56-20	10759-10760	×	_
56-21	10761-10762	3	_
56-22	10763-10765	mm	_
56-23	10766-10769	and	_
56-24	10770-10771	a	_
56-25	10772-10775	.75	_
56-26	10776-10778	mm	_
56-27	10779-10782	gap	_
56-28	10783-10790	between	_
56-29	10791-10797	slices	_
56-30	10798-10799	.	_

Text=Standard techniques were used to preprocess the functional data and used the same pipeline as previous work from our group (cf.,).
57-1	10800-10808	Standard	_
57-2	10809-10819	techniques	_
57-3	10820-10824	were	_
57-4	10825-10829	used	_
57-5	10830-10832	to	_
57-6	10833-10843	preprocess	_
57-7	10844-10847	the	_
57-8	10848-10858	functional	_
57-9	10859-10863	data	_
57-10	10864-10867	and	_
57-11	10868-10872	used	_
57-12	10873-10876	the	_
57-13	10877-10881	same	_
57-14	10882-10890	pipeline	_
57-15	10891-10893	as	_
57-16	10894-10902	previous	_
57-17	10903-10907	work	_
57-18	10908-10912	from	_
57-19	10913-10916	our	_
57-20	10917-10922	group	_
57-21	10923-10924	(	_
57-22	10925-10928	cf.	_
57-23	10929-10930	,	_
57-24	10931-10932	)	_
57-25	10933-10934	.	_

Text=This included wavelet despiking, slice timing correction, motion correction (mcflirt), brain extraction, non-linear registration of functional data to a standardized anatomical brain (MNI-152 template), spatial smoothing with FWHM of 4.25 mm (SUSAN), high pass filtering at 0.008 Hz, and rescaling to a 10,000 unit global median.
58-1	10935-10939	This	_
58-2	10940-10948	included	_
58-3	10949-10956	wavelet	_
58-4	10957-10966	despiking	_
58-5	10967-10968	,	_
58-6	10969-10974	slice	_
58-7	10975-10981	timing	_
58-8	10982-10992	correction	_
58-9	10993-10994	,	_
58-10	10995-11001	motion	_
58-11	11002-11012	correction	_
58-12	11013-11014	(	_
58-13	11015-11022	mcflirt	_
58-14	11023-11024	)	_
58-15	11025-11026	,	_
58-16	11027-11032	brain	_
58-17	11033-11043	extraction	_
58-18	11044-11045	,	_
58-19	11046-11056	non-linear	_
58-20	11057-11069	registration	_
58-21	11070-11072	of	_
58-22	11073-11083	functional	_
58-23	11084-11088	data	_
58-24	11089-11091	to	_
58-25	11092-11093	a	_
58-26	11094-11106	standardized	_
58-27	11107-11117	anatomical	_
58-28	11118-11123	brain	_
58-29	11124-11125	(	_
58-30	11126-11133	MNI-152	_
58-31	11134-11142	template	_
58-32	11143-11144	)	_
58-33	11145-11146	,	_
58-34	11147-11154	spatial	_
58-35	11155-11164	smoothing	_
58-36	11165-11169	with	_
58-37	11170-11174	FWHM	_
58-38	11175-11177	of	_
58-39	11178-11182	4.25	_
58-40	11183-11185	mm	_
58-41	11186-11187	(	_
58-42	11188-11193	SUSAN	_
58-43	11194-11195	)	_
58-44	11196-11197	,	_
58-45	11198-11202	high	_
58-46	11203-11207	pass	_
58-47	11208-11217	filtering	_
58-48	11218-11220	at	_
58-49	11221-11226	0.008	_
58-50	11227-11229	Hz	_
58-51	11230-11231	,	_
58-52	11232-11235	and	_
58-53	11236-11245	rescaling	_
58-54	11246-11248	to	_
58-55	11249-11250	a	_
58-56	11251-11257	10,000	_
58-57	11258-11262	unit	_
58-58	11263-11269	global	_
58-59	11270-11276	median	_
58-60	11277-11278	.	_

Text=Statistical analysis Selection of covariates We tested bivariate associations between usage groups (NU, EXP, REP) and our primary variables of interest (cannabis age of onset, total cannabis use) and participant demographics and characteristics as reported in Tables 1 and 2.
59-1	11279-11290	Statistical	_
59-2	11291-11299	analysis	_
59-3	11300-11309	Selection	_
59-4	11310-11312	of	_
59-5	11313-11323	covariates	_
59-6	11324-11326	We	_
59-7	11327-11333	tested	_
59-8	11334-11343	bivariate	_
59-9	11344-11356	associations	_
59-10	11357-11364	between	_
59-11	11365-11370	usage	_
59-12	11371-11377	groups	_
59-13	11378-11379	(	_
59-14	11380-11382	NU	_
59-15	11383-11384	,	_
59-16	11385-11388	EXP	_
59-17	11389-11390	,	_
59-18	11391-11394	REP	_
59-19	11395-11396	)	_
59-20	11397-11400	and	_
59-21	11401-11404	our	_
59-22	11405-11412	primary	_
59-23	11413-11422	variables	_
59-24	11423-11425	of	_
59-25	11426-11434	interest	_
59-26	11435-11436	(	_
59-27	11437-11445	cannabis	_
59-28	11446-11449	age	_
59-29	11450-11452	of	_
59-30	11453-11458	onset	_
59-31	11459-11460	,	_
59-32	11461-11466	total	_
59-33	11467-11475	cannabis	_
59-34	11476-11479	use	_
59-35	11480-11481	)	_
59-36	11482-11485	and	_
59-37	11486-11497	participant	_
59-38	11498-11510	demographics	_
59-39	11511-11514	and	_
59-40	11515-11530	characteristics	_
59-41	11531-11533	as	_
59-42	11534-11542	reported	_
59-43	11543-11545	in	_
59-44	11546-11552	Tables	_
59-45	11553-11554	1	_
59-46	11555-11558	and	_
59-47	11559-11560	2	_
59-48	11561-11562	.	_

Text=For associations with categorical usage groups (NU, EXP, REP), statistical testing utilized Welch ’ s unequal variance t-test (continuous variables), Mann-Whitney U (substance use measures), or Fisher ’ s exact test (categorical variables).
60-1	11563-11566	For	_
60-2	11567-11579	associations	_
60-3	11580-11584	with	_
60-4	11585-11596	categorical	_
60-5	11597-11602	usage	_
60-6	11603-11609	groups	_
60-7	11610-11611	(	_
60-8	11612-11614	NU	_
60-9	11615-11616	,	_
60-10	11617-11620	EXP	_
60-11	11621-11622	,	_
60-12	11623-11626	REP	_
60-13	11627-11628	)	_
60-14	11629-11630	,	_
60-15	11631-11642	statistical	_
60-16	11643-11650	testing	_
60-17	11651-11659	utilized	_
60-18	11660-11665	Welch	_
60-19	11666-11667	’	_
60-20	11668-11669	s	_
60-21	11670-11677	unequal	_
60-22	11678-11686	variance	_
60-23	11687-11693	t-test	_
60-24	11694-11695	(	_
60-25	11696-11706	continuous	_
60-26	11707-11716	variables	_
60-27	11717-11718	)	_
60-28	11719-11720	,	_
60-29	11721-11733	Mann-Whitney	_
60-30	11734-11735	U	_
60-31	11736-11737	(	_
60-32	11738-11747	substance	_
60-33	11748-11751	use	_
60-34	11752-11760	measures	_
60-35	11761-11762	)	_
60-36	11763-11764	,	_
60-37	11765-11767	or	_
60-38	11768-11774	Fisher	_
60-39	11775-11776	’	_
60-40	11777-11778	s	_
60-41	11779-11784	exact	_
60-42	11785-11789	test	_
60-43	11790-11791	(	_
60-44	11792-11803	categorical	_
60-45	11804-11813	variables	_
60-46	11814-11815	)	_
60-47	11816-11817	.	_

Text=For bivariate associations with continuous cannabis use measures (cannabis age of onset, total cannabis), statistical testing utilized Pearson correlation (continuous variables) and Welch ’ s unequal variance t-test (categorical variables).
61-1	11818-11821	For	_
61-2	11822-11831	bivariate	_
61-3	11832-11844	associations	_
61-4	11845-11849	with	_
61-5	11850-11860	continuous	_
61-6	11861-11869	cannabis	_
61-7	11870-11873	use	_
61-8	11874-11882	measures	_
61-9	11883-11884	(	_
61-10	11885-11893	cannabis	_
61-11	11894-11897	age	_
61-12	11898-11900	of	_
61-13	11901-11906	onset	_
61-14	11907-11908	,	_
61-15	11909-11914	total	_
61-16	11915-11923	cannabis	_
61-17	11924-11925	)	_
61-18	11926-11927	,	_
61-19	11928-11939	statistical	_
61-20	11940-11947	testing	_
61-21	11948-11956	utilized	_
61-22	11957-11964	Pearson	_
61-23	11965-11976	correlation	_
61-24	11977-11978	(	_
61-25	11979-11989	continuous	_
61-26	11990-11999	variables	_
61-27	12000-12001	)	_
61-28	12002-12005	and	_
61-29	12006-12011	Welch	_
61-30	12012-12013	’	_
61-31	12014-12015	s	_
61-32	12016-12023	unequal	_
61-33	12024-12032	variance	_
61-34	12033-12039	t-test	_
61-35	12040-12041	(	_
61-36	12042-12053	categorical	_
61-37	12054-12063	variables	_
61-38	12064-12065	)	_
61-39	12066-12067	.	_

Text=Any measures that had a significant or trending association (p <.10, uncorrected) to cannabis age of onset or total cannabis use and/or distinguished usage groups (Tables 1 and 2) were used as covariates in behavior and neuroimaging analysis according to the procedures outlined below.
62-1	12068-12071	Any	_
62-2	12072-12080	measures	_
62-3	12081-12085	that	_
62-4	12086-12089	had	_
62-5	12090-12091	a	_
62-6	12092-12103	significant	_
62-7	12104-12106	or	_
62-8	12107-12115	trending	_
62-9	12116-12127	association	_
62-10	12128-12129	(	_
62-11	12130-12131	p	_
62-12	12132-12133	<	_
62-13	12134-12137	.10	_
62-14	12138-12139	,	_
62-15	12140-12151	uncorrected	_
62-16	12152-12153	)	_
62-17	12154-12156	to	_
62-18	12157-12165	cannabis	_
62-19	12166-12169	age	_
62-20	12170-12172	of	_
62-21	12173-12178	onset	_
62-22	12179-12181	or	_
62-23	12182-12187	total	_
62-24	12188-12196	cannabis	_
62-25	12197-12200	use	_
62-26	12201-12207	and/or	_
62-27	12208-12221	distinguished	_
62-28	12222-12227	usage	_
62-29	12228-12234	groups	_
62-30	12235-12236	(	_
62-31	12237-12243	Tables	_
62-32	12244-12245	1	_
62-33	12246-12249	and	_
62-34	12250-12251	2	_
62-35	12252-12253	)	_
62-36	12254-12258	were	_
62-37	12259-12263	used	_
62-38	12264-12266	as	_
62-39	12267-12277	covariates	_
62-40	12278-12280	in	_
62-41	12281-12289	behavior	_
62-42	12290-12293	and	_
62-43	12294-12306	neuroimaging	_
62-44	12307-12315	analysis	_
62-45	12316-12325	according	_
62-46	12326-12328	to	_
62-47	12329-12332	the	_
62-48	12333-12343	procedures	_
62-49	12344-12352	outlined	_
62-50	12353-12358	below	_
62-51	12359-12360	.	_

Text=Based on this covariate testing procedure, for cannabis age of onset analyses, highest level of education, total cigarette use, cigarette use within the last year, other drug use, and cannabis group (EXP/REP) were used as covariates (covariate set A).
63-1	12361-12366	Based	_
63-2	12367-12369	on	_
63-3	12370-12374	this	_
63-4	12375-12384	covariate	_
63-5	12385-12392	testing	_
63-6	12393-12402	procedure	_
63-7	12403-12404	,	_
63-8	12405-12408	for	_
63-9	12409-12417	cannabis	_
63-10	12418-12421	age	_
63-11	12422-12424	of	_
63-12	12425-12430	onset	_
63-13	12431-12439	analyses	_
63-14	12440-12441	,	_
63-15	12442-12449	highest	_
63-16	12450-12455	level	_
63-17	12456-12458	of	_
63-18	12459-12468	education	_
63-19	12469-12470	,	_
63-20	12471-12476	total	_
63-21	12477-12486	cigarette	_
63-22	12487-12490	use	_
63-23	12491-12492	,	_
63-24	12493-12502	cigarette	_
63-25	12503-12506	use	_
63-26	12507-12513	within	_
63-27	12514-12517	the	_
63-28	12518-12522	last	_
63-29	12523-12527	year	_
63-30	12528-12529	,	_
63-31	12530-12535	other	_
63-32	12536-12540	drug	_
63-33	12541-12544	use	_
63-34	12545-12546	,	_
63-35	12547-12550	and	_
63-36	12551-12559	cannabis	_
63-37	12560-12565	group	_
63-38	12566-12567	(	_
63-39	12568-12575	EXP/REP	_
63-40	12576-12577	)	_
63-41	12578-12582	were	_
63-42	12583-12587	used	_
63-43	12588-12590	as	_
63-44	12591-12601	covariates	_
63-45	12602-12603	(	_
63-46	12604-12613	covariate	_
63-47	12614-12617	set	_
63-48	12618-12619	A	_
63-49	12620-12621	)	_
63-50	12622-12623	.	_

Text=For total cannabis use analysis, highest level of education, family income, cannabis age of onset (see below), cannabis use within the last year, total alcohol use, total cigarette use, cigarette use within the last year, and other drug used were used as covariates (covariate set B).
64-1	12624-12627	For	_
64-2	12628-12633	total	_
64-3	12634-12642	cannabis	_
64-4	12643-12646	use	_
64-5	12647-12655	analysis	_
64-6	12656-12657	,	_
64-7	12658-12665	highest	_
64-8	12666-12671	level	_
64-9	12672-12674	of	_
64-10	12675-12684	education	_
64-11	12685-12686	,	_
64-12	12687-12693	family	_
64-13	12694-12700	income	_
64-14	12701-12702	,	_
64-15	12703-12711	cannabis	_
64-16	12712-12715	age	_
64-17	12716-12718	of	_
64-18	12719-12724	onset	_
64-19	12725-12726	(	_
64-20	12727-12730	see	_
64-21	12731-12736	below	_
64-22	12737-12738	)	_
64-23	12739-12740	,	_
64-24	12741-12749	cannabis	_
64-25	12750-12753	use	_
64-26	12754-12760	within	_
64-27	12761-12764	the	_
64-28	12765-12769	last	_
64-29	12770-12774	year	_
64-30	12775-12776	,	_
64-31	12777-12782	total	_
64-32	12783-12790	alcohol	_
64-33	12791-12794	use	_
64-34	12795-12796	,	_
64-35	12797-12802	total	_
64-36	12803-12812	cigarette	_
64-37	12813-12816	use	_
64-38	12817-12818	,	_
64-39	12819-12828	cigarette	_
64-40	12829-12832	use	_
64-41	12833-12839	within	_
64-42	12840-12843	the	_
64-43	12844-12848	last	_
64-44	12849-12853	year	_
64-45	12854-12855	,	_
64-46	12856-12859	and	_
64-47	12860-12865	other	_
64-48	12866-12870	drug	_
64-49	12871-12875	used	_
64-50	12876-12880	were	_
64-51	12881-12885	used	_
64-52	12886-12888	as	_
64-53	12889-12899	covariates	_
64-54	12900-12901	(	_
64-55	12902-12911	covariate	_
64-56	12912-12915	set	_
64-57	12916-12917	B	_
64-58	12918-12919	)	_
64-59	12920-12921	.	_

Text=One subject (cannabis age of onset = 12.33, REP) was missing highest level of education data and was therefore not included in covariate models with this measure.
65-1	12922-12925	One	_
65-2	12926-12933	subject	_
65-3	12934-12935	(	_
65-4	12936-12944	cannabis	_
65-5	12945-12948	age	_
65-6	12949-12951	of	_
65-7	12952-12957	onset	_
65-8	12958-12959	=	_
65-9	12960-12965	12.33	_
65-10	12966-12967	,	_
65-11	12968-12971	REP	_
65-12	12972-12973	)	_
65-13	12974-12977	was	_
65-14	12978-12985	missing	_
65-15	12986-12993	highest	_
65-16	12994-12999	level	_
65-17	13000-13002	of	_
65-18	13003-13012	education	_
65-19	13013-13017	data	_
65-20	13018-13021	and	_
65-21	13022-13025	was	_
65-22	13026-13035	therefore	_
65-23	13036-13039	not	_
65-24	13040-13048	included	_
65-25	13049-13051	in	_
65-26	13052-13061	covariate	_
65-27	13062-13068	models	_
65-28	13069-13073	with	_
65-29	13074-13078	this	_
65-30	13079-13086	measure	_
65-31	13087-13088	.	_

Text=See Supplemental Table 1:4 for significance of covariates in primary cannabis age of onset and total cannabis use analyses.
66-1	13089-13092	See	_
66-2	13093-13105	Supplemental	_
66-3	13106-13111	Table	_
66-4	13112-13115	1:4	_
66-5	13116-13119	for	_
66-6	13120-13132	significance	_
66-7	13133-13135	of	_
66-8	13136-13146	covariates	_
66-9	13147-13149	in	_
66-10	13150-13157	primary	_
66-11	13158-13166	cannabis	_
66-12	13167-13170	age	_
66-13	13171-13173	of	_
66-14	13174-13179	onset	_
66-15	13180-13183	and	_
66-16	13184-13189	total	_
66-17	13190-13198	cannabis	_
66-18	13199-13202	use	_
66-19	13203-13211	analyses	_
66-20	13212-13213	.	_

Text=For comparison between usage groups (NU, EXP, REP), total alcohol use, alcohol use within the last year, total cigarette use, and cigarette use within the last year were used as covariates (covariate set C).
67-1	13214-13217	For	_
67-2	13218-13228	comparison	_
67-3	13229-13236	between	_
67-4	13237-13242	usage	_
67-5	13243-13249	groups	_
67-6	13250-13251	(	_
67-7	13252-13254	NU	_
67-8	13255-13256	,	_
67-9	13257-13260	EXP	_
67-10	13261-13262	,	_
67-11	13263-13266	REP	_
67-12	13267-13268	)	_
67-13	13269-13270	,	_
67-14	13271-13276	total	_
67-15	13277-13284	alcohol	_
67-16	13285-13288	use	_
67-17	13289-13290	,	_
67-18	13291-13298	alcohol	_
67-19	13299-13302	use	_
67-20	13303-13309	within	_
67-21	13310-13313	the	_
67-22	13314-13318	last	_
67-23	13319-13323	year	_
67-24	13324-13325	,	_
67-25	13326-13331	total	_
67-26	13332-13341	cigarette	_
67-27	13342-13345	use	_
67-28	13346-13347	,	_
67-29	13348-13351	and	_
67-30	13352-13361	cigarette	_
67-31	13362-13365	use	_
67-32	13366-13372	within	_
67-33	13373-13376	the	_
67-34	13377-13381	last	_
67-35	13382-13386	year	_
67-36	13387-13391	were	_
67-37	13392-13396	used	_
67-38	13397-13399	as	_
67-39	13400-13410	covariates	_
67-40	13411-13412	(	_
67-41	13413-13422	covariate	_
67-42	13423-13426	set	_
67-43	13427-13428	C	_
67-44	13429-13430	)	_
67-45	13431-13432	.	_

Text=Of note, the NU group contained a small proportion of men (2 out of 15).
68-1	13433-13435	Of	_
68-2	13436-13440	note	_
68-3	13441-13442	,	_
68-4	13443-13446	the	_
68-5	13447-13449	NU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
68-6	13450-13455	group	_
68-7	13456-13465	contained	_
68-8	13466-13467	a	_
68-9	13468-13473	small	_
68-10	13474-13484	proportion	_
68-11	13485-13487	of	_
68-12	13488-13491	men	_
68-13	13492-13493	(	_
68-14	13494-13495	2	_
68-15	13496-13499	out	_
68-16	13500-13502	of	_
68-17	13503-13505	15	_
68-18	13506-13507	)	_
68-19	13508-13509	.	_

Text=Therefore, instead of model adjustment, secondary analyses were run including only women when comparing NU, REP, and EXP.
69-1	13510-13519	Therefore	_
69-2	13520-13521	,	_
69-3	13522-13529	instead	_
69-4	13530-13532	of	_
69-5	13533-13538	model	_
69-6	13539-13549	adjustment	_
69-7	13550-13551	,	_
69-8	13552-13561	secondary	_
69-9	13562-13570	analyses	_
69-10	13571-13575	were	_
69-11	13576-13579	run	_
69-12	13580-13589	including	_
69-13	13590-13594	only	_
69-14	13595-13600	women	_
69-15	13601-13605	when	_
69-16	13606-13615	comparing	_
69-17	13616-13618	NU	_
69-18	13619-13620	,	_
69-19	13621-13624	REP	_
69-20	13625-13626	,	_
69-21	13627-13630	and	_
69-22	13631-13634	EXP	_
69-23	13635-13636	.	_

Text=Additionally, given the MHCPD assessment of prenatal exposure, which has been associated with IQ and WM, secondary analyses were also run with prenatal cannabis, alcohol, and cigarette exposure as covariates and moderators when examining both cannabis age of onset and total cannabis use (Supplemental Fig.
70-1	13637-13649	Additionally	_
70-2	13650-13651	,	_
70-3	13652-13657	given	_
70-4	13658-13661	the	_
70-5	13662-13667	MHCPD	_
70-6	13668-13678	assessment	_
70-7	13679-13681	of	_
70-8	13682-13690	prenatal	_
70-9	13691-13699	exposure	_
70-10	13700-13701	,	_
70-11	13702-13707	which	_
70-12	13708-13711	has	_
70-13	13712-13716	been	_
70-14	13717-13727	associated	_
70-15	13728-13732	with	_
70-16	13733-13735	IQ	_
70-17	13736-13739	and	_
70-18	13740-13742	WM	_
70-19	13743-13744	,	_
70-20	13745-13754	secondary	_
70-21	13755-13763	analyses	_
70-22	13764-13768	were	_
70-23	13769-13773	also	_
70-24	13774-13777	run	_
70-25	13778-13782	with	_
70-26	13783-13791	prenatal	_
70-27	13792-13800	cannabis	_
70-28	13801-13802	,	_
70-29	13803-13810	alcohol	_
70-30	13811-13812	,	_
70-31	13813-13816	and	_
70-32	13817-13826	cigarette	_
70-33	13827-13835	exposure	_
70-34	13836-13838	as	_
70-35	13839-13849	covariates	_
70-36	13850-13853	and	_
70-37	13854-13864	moderators	_
70-38	13865-13869	when	_
70-39	13870-13879	examining	_
70-40	13880-13884	both	_
70-41	13885-13893	cannabis	_
70-42	13894-13897	age	_
70-43	13898-13900	of	_
70-44	13901-13906	onset	_
70-45	13907-13910	and	_
70-46	13911-13916	total	_
70-47	13917-13925	cannabis	_
70-48	13926-13929	use	_
70-49	13930-13931	(	_
70-50	13932-13944	Supplemental	_
70-51	13945-13948	Fig	_
70-52	13949-13950	.	_

Text=S2).
71-1	13951-13953	S2	_
71-2	13954-13955	)	_
71-3	13956-13957	.	_

Text=Furthermore, based on the reviewed literature (cf.,) and the differences in cannabis age of onset between EXP and REP (Table 1), we performed secondary analysis examining cannabis age of onset associations in the REP group while covarying total cannabis use.
72-1	13958-13969	Furthermore	_
72-2	13970-13971	,	_
72-3	13972-13977	based	_
72-4	13978-13980	on	_
72-5	13981-13984	the	_
72-6	13985-13993	reviewed	_
72-7	13994-14004	literature	_
72-8	14005-14006	(	_
72-9	14007-14010	cf.	_
72-10	14011-14012	,	_
72-11	14013-14014	)	_
72-12	14015-14018	and	_
72-13	14019-14022	the	_
72-14	14023-14034	differences	_
72-15	14035-14037	in	_
72-16	14038-14046	cannabis	_
72-17	14047-14050	age	_
72-18	14051-14053	of	_
72-19	14054-14059	onset	_
72-20	14060-14067	between	_
72-21	14068-14071	EXP	_
72-22	14072-14075	and	_
72-23	14076-14079	REP	_
72-24	14080-14081	(	_
72-25	14082-14087	Table	_
72-26	14088-14089	1	_
72-27	14090-14091	)	_
72-28	14092-14093	,	_
72-29	14094-14096	we	_
72-30	14097-14106	performed	_
72-31	14107-14116	secondary	_
72-32	14117-14125	analysis	_
72-33	14126-14135	examining	_
72-34	14136-14144	cannabis	_
72-35	14145-14148	age	_
72-36	14149-14151	of	_
72-37	14152-14157	onset	_
72-38	14158-14170	associations	_
72-39	14171-14173	in	_
72-40	14174-14177	the	_
72-41	14178-14181	REP	_
72-42	14182-14187	group	_
72-43	14188-14193	while	_
72-44	14194-14203	covarying	_
72-45	14204-14209	total	_
72-46	14210-14218	cannabis	_
72-47	14219-14222	use	_
72-48	14223-14224	.	_

Text=Finally, one subject (cannabis age of onset =13.75, REP) reported use of a drug other than cannabis, alcohol, or cigarettes during the year prior to testing (recreational use of opioid pain medication).
73-1	14225-14232	Finally	_
73-2	14233-14234	,	_
73-3	14235-14238	one	_
73-4	14239-14246	subject	_
73-5	14247-14248	(	_
73-6	14249-14257	cannabis	_
73-7	14258-14261	age	_
73-8	14262-14264	of	_
73-9	14265-14270	onset	_
73-10	14271-14277	=13.75	_
73-11	14278-14279	,	_
73-12	14280-14283	REP	_
73-13	14284-14285	)	_
73-14	14286-14294	reported	_
73-15	14295-14298	use	_
73-16	14299-14301	of	_
73-17	14302-14303	a	_
73-18	14304-14308	drug	_
73-19	14309-14314	other	_
73-20	14315-14319	than	_
73-21	14320-14328	cannabis	_
73-22	14329-14330	,	_
73-23	14331-14338	alcohol	_
73-24	14339-14340	,	_
73-25	14341-14343	or	_
73-26	14344-14354	cigarettes	_
73-27	14355-14361	during	_
73-28	14362-14365	the	_
73-29	14366-14370	year	_
73-30	14371-14376	prior	_
73-31	14377-14379	to	_
73-32	14380-14387	testing	_
73-33	14388-14389	(	_
73-34	14390-14402	recreational	_
73-35	14403-14406	use	_
73-36	14407-14409	of	_
73-37	14410-14416	opioid	_
73-38	14417-14421	pain	_
73-39	14422-14432	medication	_
73-40	14433-14434	)	_
73-41	14435-14436	.	_

Text=The pattern of significant results was unchanged when excluding this subject.
74-1	14437-14440	The	_
74-2	14441-14448	pattern	_
74-3	14449-14451	of	_
74-4	14452-14463	significant	_
74-5	14464-14471	results	_
74-6	14472-14475	was	_
74-7	14476-14485	unchanged	_
74-8	14486-14490	when	_
74-9	14491-14500	excluding	_
74-10	14501-14505	this	_
74-11	14506-14513	subject	_
74-12	14514-14515	.	_

Text=WM behavior Primary behavioral analysis was performed in R 3.1.2.
75-1	14516-14518	WM	_
75-2	14519-14527	behavior	_
75-3	14528-14535	Primary	_
75-4	14536-14546	behavioral	_
75-5	14547-14555	analysis	_
75-6	14556-14559	was	_
75-7	14560-14569	performed	_
75-8	14570-14572	in	_
75-9	14573-14574	R	_
75-10	14575-14580	3.1.2	_
75-11	14581-14582	.	_

Text=Mixed-effects models (lme4 package) were used to examine main effects and interactions between task conditions and categorical (NU, EXP, REP) and continuous (age of onset, total cannabis use) cannabis measures.
76-1	14583-14596	Mixed-effects	_
76-2	14597-14603	models	_
76-3	14604-14605	(	_
76-4	14606-14610	lme4	_
76-5	14611-14618	package	_
76-6	14619-14620	)	_
76-7	14621-14625	were	_
76-8	14626-14630	used	_
76-9	14631-14633	to	_
76-10	14634-14641	examine	_
76-11	14642-14646	main	_
76-12	14647-14654	effects	_
76-13	14655-14658	and	_
76-14	14659-14671	interactions	_
76-15	14672-14679	between	_
76-16	14680-14684	task	_
76-17	14685-14695	conditions	_
76-18	14696-14699	and	_
76-19	14700-14711	categorical	_
76-20	14712-14713	(	_
76-21	14714-14716	NU	_
76-22	14717-14718	,	_
76-23	14719-14722	EXP	_
76-24	14723-14724	,	_
76-25	14725-14728	REP	_
76-26	14729-14730	)	_
76-27	14731-14734	and	_
76-28	14735-14745	continuous	_
76-29	14746-14747	(	_
76-30	14748-14751	age	_
76-31	14752-14754	of	_
76-32	14755-14760	onset	_
76-33	14761-14762	,	_
76-34	14763-14768	total	_
76-35	14769-14777	cannabis	_
76-36	14778-14781	use	_
76-37	14782-14783	)	_
76-38	14784-14792	cannabis	_
76-39	14793-14801	measures	_
76-40	14802-14803	.	_

Text=Accuracy data were analyzed using a generalized-linear mixed-effects model with a logit link function since trial level data were binomially distributed (correct vs. incorrect).
77-1	14804-14812	Accuracy	_
77-2	14813-14817	data	_
77-3	14818-14822	were	_
77-4	14823-14831	analyzed	_
77-5	14832-14837	using	_
77-6	14838-14839	a	_
77-7	14840-14858	generalized-linear	_
77-8	14859-14872	mixed-effects	_
77-9	14873-14878	model	_
77-10	14879-14883	with	_
77-11	14884-14885	a	_
77-12	14886-14891	logit	_
77-13	14892-14896	link	_
77-14	14897-14905	function	_
77-15	14906-14911	since	_
77-16	14912-14917	trial	_
77-17	14918-14923	level	_
77-18	14924-14928	data	_
77-19	14929-14933	were	_
77-20	14934-14944	binomially	_
77-21	14945-14956	distributed	_
77-22	14957-14958	(	_
77-23	14959-14966	correct	_
77-24	14967-14970	vs.	_
77-25	14971-14980	incorrect	_
77-26	14981-14982	)	_
77-27	14983-14984	.	_

Text=Trials with omission errors (4.02% of all trials) were excluded from the accuracy analysis, where omissions were not counted toward the trial count (see Supplemental Tables 5 and 6 for omission error analysis).
78-1	14985-14991	Trials	_
78-2	14992-14996	with	_
78-3	14997-15005	omission	_
78-4	15006-15012	errors	_
78-5	15013-15014	(	_
78-6	15015-15019	4.02	_
78-7	15020-15021	%	_
78-8	15022-15024	of	_
78-9	15025-15028	all	_
78-10	15029-15035	trials	_
78-11	15036-15037	)	_
78-12	15038-15042	were	_
78-13	15043-15051	excluded	_
78-14	15052-15056	from	_
78-15	15057-15060	the	_
78-16	15061-15069	accuracy	_
78-17	15070-15078	analysis	_
78-18	15079-15080	,	_
78-19	15081-15086	where	_
78-20	15087-15096	omissions	_
78-21	15097-15101	were	_
78-22	15102-15105	not	_
78-23	15106-15113	counted	_
78-24	15114-15120	toward	_
78-25	15121-15124	the	_
78-26	15125-15130	trial	_
78-27	15131-15136	count	_
78-28	15137-15138	(	_
78-29	15139-15142	see	_
78-30	15143-15155	Supplemental	_
78-31	15156-15162	Tables	_
78-32	15163-15164	5	_
78-33	15165-15168	and	_
78-34	15169-15170	6	_
78-35	15171-15174	for	_
78-36	15175-15183	omission	_
78-37	15184-15189	error	_
78-38	15190-15198	analysis	_
78-39	15199-15200	)	_
78-40	15201-15202	.	_

Text=Reaction time data were log transformed to reduce heteroscedasticity of residuals and analyzed using a linear mixed-effects model including only correct trials.
79-1	15203-15211	Reaction	_
79-2	15212-15216	time	_
79-3	15217-15221	data	_
79-4	15222-15226	were	_
79-5	15227-15230	log	_
79-6	15231-15242	transformed	_
79-7	15243-15245	to	_
79-8	15246-15252	reduce	_
79-9	15253-15271	heteroscedasticity	_
79-10	15272-15274	of	_
79-11	15275-15284	residuals	_
79-12	15285-15288	and	_
79-13	15289-15297	analyzed	_
79-14	15298-15303	using	_
79-15	15304-15305	a	_
79-16	15306-15312	linear	_
79-17	15313-15326	mixed-effects	_
79-18	15327-15332	model	_
79-19	15333-15342	including	_
79-20	15343-15347	only	_
79-21	15348-15355	correct	_
79-22	15356-15362	trials	_
79-23	15363-15364	.	_

Text=Both linear- and generalized-linear mixed-effects models were estimated with maximum likelihood.
80-1	15365-15369	Both	_
80-2	15370-15377	linear-	_
80-3	15378-15381	and	_
80-4	15382-15400	generalized-linear	_
80-5	15401-15414	mixed-effects	_
80-6	15415-15421	models	_
80-7	15422-15426	were	_
80-8	15427-15436	estimated	_
80-9	15437-15441	with	_
80-10	15442-15449	maximum	_
80-11	15450-15460	likelihood	_
80-12	15461-15462	.	_

Text=Random intercepts were estimated for each subject.
81-1	15463-15469	Random	_
81-2	15470-15480	intercepts	_
81-3	15481-15485	were	_
81-4	15486-15495	estimated	_
81-5	15496-15499	for	_
81-6	15500-15504	each	_
81-7	15505-15512	subject	_
81-8	15513-15514	.	_

Text=Task conditions (load, delay length, cue validity), cannabis measures, and covariates were included as fixed effects in two phases: a baseline model, with only the task conditions and cannabis measure in question, and a full model with all potential confounding variables as covariates (see Tables 1 and 2).
82-1	15515-15519	Task	_
82-2	15520-15530	conditions	_
82-3	15531-15532	(	_
82-4	15533-15537	load	_
82-5	15538-15539	,	_
82-6	15540-15545	delay	_
82-7	15546-15552	length	_
82-8	15553-15554	,	_
82-9	15555-15558	cue	_
82-10	15559-15567	validity	_
82-11	15568-15569	)	_
82-12	15570-15571	,	_
82-13	15572-15580	cannabis	_
82-14	15581-15589	measures	_
82-15	15590-15591	,	_
82-16	15592-15595	and	_
82-17	15596-15606	covariates	_
82-18	15607-15611	were	_
82-19	15612-15620	included	_
82-20	15621-15623	as	_
82-21	15624-15629	fixed	_
82-22	15630-15637	effects	_
82-23	15638-15640	in	_
82-24	15641-15644	two	_
82-25	15645-15651	phases	_
82-26	15652-15653	:	_
82-27	15654-15655	a	_
82-28	15656-15664	baseline	_
82-29	15665-15670	model	_
82-30	15671-15672	,	_
82-31	15673-15677	with	_
82-32	15678-15682	only	_
82-33	15683-15686	the	_
82-34	15687-15691	task	_
82-35	15692-15702	conditions	_
82-36	15703-15706	and	_
82-37	15707-15715	cannabis	_
82-38	15716-15723	measure	_
82-39	15724-15726	in	_
82-40	15727-15735	question	_
82-41	15736-15737	,	_
82-42	15738-15741	and	_
82-43	15742-15743	a	_
82-44	15744-15748	full	_
82-45	15749-15754	model	_
82-46	15755-15759	with	_
82-47	15760-15763	all	_
82-48	15764-15773	potential	_
82-49	15774-15785	confounding	_
82-50	15786-15795	variables	_
82-51	15796-15798	as	_
82-52	15799-15809	covariates	_
82-53	15810-15811	(	_
82-54	15812-15815	see	_
82-55	15816-15822	Tables	_
82-56	15823-15824	1	_
82-57	15825-15828	and	_
82-58	15829-15830	2	_
82-59	15831-15832	)	_
82-60	15833-15834	.	_

Text=Significance values for fixed effects were obtained through the car package (chi-square test).
83-1	15835-15847	Significance	_
83-2	15848-15854	values	_
83-3	15855-15858	for	_
83-4	15859-15864	fixed	_
83-5	15865-15872	effects	_
83-6	15873-15877	were	_
83-7	15878-15886	obtained	_
83-8	15887-15894	through	_
83-9	15895-15898	the	_
83-10	15899-15902	car	_
83-11	15903-15910	package	_
83-12	15911-15912	(	_
83-13	15913-15923	chi-square	_
83-14	15924-15928	test	_
83-15	15929-15930	)	_
83-16	15931-15932	.	_

Text=Simple effects were obtained through the lsmeans package.
84-1	15933-15939	Simple	_
84-2	15940-15947	effects	_
84-3	15948-15952	were	_
84-4	15953-15961	obtained	_
84-5	15962-15969	through	_
84-6	15970-15973	the	_
84-7	15974-15981	lsmeans	_
84-8	15982-15989	package	_
84-9	15990-15991	.	_

Text=Potential influential observations were examined using Cook ’ s distance and dfbetas (both cutoffs> 1) on mean performance measures.
85-1	15992-16001	Potential	_
85-2	16002-16013	influential	_
85-3	16014-16026	observations	_
85-4	16027-16031	were	_
85-5	16032-16040	examined	_
85-6	16041-16046	using	_
85-7	16047-16051	Cook	_
85-8	16052-16053	’	_
85-9	16054-16055	s	_
85-10	16056-16064	distance	_
85-11	16065-16068	and	_
85-12	16069-16076	dfbetas	_
85-13	16077-16078	(	_
85-14	16079-16083	both	_
85-15	16084-16091	cutoffs	_
85-16	16092-16093	>	_
85-17	16094-16095	1	_
85-18	16096-16097	)	_
85-19	16098-16100	on	_
85-20	16101-16105	mean	_
85-21	16106-16117	performance	_
85-22	16118-16126	measures	_
85-23	16127-16128	.	_

Text=No subjects exceeded these thresholds.
86-1	16129-16131	No	_
86-2	16132-16140	subjects	_
86-3	16141-16149	exceeded	_
86-4	16150-16155	these	_
86-5	16156-16166	thresholds	_
86-6	16167-16168	.	_

Text=WMfMRI All imaging analysis was performed with Analysis and Visualization of Functional Neuroimages (AFNI, Bethesda, MD) software.
87-1	16169-16175	WMfMRI	_
87-2	16176-16179	All	_
87-3	16180-16187	imaging	_
87-4	16188-16196	analysis	_
87-5	16197-16200	was	_
87-6	16201-16210	performed	_
87-7	16211-16215	with	_
87-8	16216-16224	Analysis	_
87-9	16225-16228	and	_
87-10	16229-16242	Visualization	_
87-11	16243-16245	of	_
87-12	16246-16256	Functional	_
87-13	16257-16268	Neuroimages	_
87-14	16269-16270	(	_
87-15	16271-16275	AFNI	_
87-16	16276-16277	,	_
87-17	16278-16286	Bethesda	_
87-18	16287-16288	,	_
87-19	16289-16291	MD	_
87-20	16292-16293	)	_
87-21	16294-16302	software	_
87-22	16303-16304	.	_

Text=In order to estimate the BOLD response at both the trial- and WM epoch-level (cue, delay, target), two level-1 GLM analyses were run for every subject using AFNI ’ s 3dDeconvolve tool.
88-1	16305-16307	In	_
88-2	16308-16313	order	_
88-3	16314-16316	to	_
88-4	16317-16325	estimate	_
88-5	16326-16329	the	_
88-6	16330-16334	BOLD	_
88-7	16335-16343	response	_
88-8	16344-16346	at	_
88-9	16347-16351	both	_
88-10	16352-16355	the	_
88-11	16356-16362	trial-	_
88-12	16363-16366	and	_
88-13	16367-16369	WM	_
88-14	16370-16381	epoch-level	_
88-15	16382-16383	(	_
88-16	16384-16387	cue	_
88-17	16388-16389	,	_
88-18	16390-16395	delay	_
88-19	16396-16397	,	_
88-20	16398-16404	target	_
88-21	16405-16406	)	_
88-22	16407-16408	,	_
88-23	16409-16412	two	_
88-24	16413-16420	level-1	_
88-25	16421-16424	GLM	_
88-26	16425-16433	analyses	_
88-27	16434-16438	were	_
88-28	16439-16442	run	_
88-29	16443-16446	for	_
88-30	16447-16452	every	_
88-31	16453-16460	subject	_
88-32	16461-16466	using	_
88-33	16467-16471	AFNI	_
88-34	16472-16473	’	_
88-35	16474-16475	s	_
88-36	16476-16488	3dDeconvolve	_
88-37	16489-16493	tool	_
88-38	16494-16495	.	_

Text=GLM-1.
89-1	16496-16501	GLM-1	_
89-2	16502-16503	.	_

Text=To estimate the average HRF response to the task, trial time courses for correct, incorrect, and partial trials were modeled using TENT basis functions spanning 28 s with 15 time steps.
90-1	16504-16506	To	_
90-2	16507-16515	estimate	_
90-3	16516-16519	the	_
90-4	16520-16527	average	_
90-5	16528-16531	HRF	_
90-6	16532-16540	response	_
90-7	16541-16543	to	_
90-8	16544-16547	the	_
90-9	16548-16552	task	_
90-10	16553-16554	,	_
90-11	16555-16560	trial	_
90-12	16561-16565	time	_
90-13	16566-16573	courses	_
90-14	16574-16577	for	_
90-15	16578-16585	correct	_
90-16	16586-16587	,	_
90-17	16588-16597	incorrect	_
90-18	16598-16599	,	_
90-19	16600-16603	and	_
90-20	16604-16611	partial	_
90-21	16612-16618	trials	_
90-22	16619-16623	were	_
90-23	16624-16631	modeled	_
90-24	16632-16637	using	_
90-25	16638-16642	TENT	_
90-26	16643-16648	basis	_
90-27	16649-16658	functions	_
90-28	16659-16667	spanning	_
90-29	16668-16670	28	_
90-30	16671-16672	s	_
90-31	16673-16677	with	_
90-32	16678-16680	15	_
90-33	16681-16685	time	_
90-34	16686-16691	steps	_
90-35	16692-16693	.	_

Text=Due to the temporal properties of the HRF, conditions with different durations were modeled separately (1500 ms and 6000 ms delay trials).
91-1	16694-16697	Due	_
91-2	16698-16700	to	_
91-3	16701-16704	the	_
91-4	16705-16713	temporal	_
91-5	16714-16724	properties	_
91-6	16725-16727	of	_
91-7	16728-16731	the	_
91-8	16732-16735	HRF	_
91-9	16736-16737	,	_
91-10	16738-16748	conditions	_
91-11	16749-16753	with	_
91-12	16754-16763	different	_
91-13	16764-16773	durations	_
91-14	16774-16778	were	_
91-15	16779-16786	modeled	_
91-16	16787-16797	separately	_
91-17	16798-16799	(	_
91-18	16800-16804	1500	_
91-19	16805-16807	ms	_
91-20	16808-16811	and	_
91-21	16812-16816	6000	_
91-22	16817-16819	ms	_
91-23	16820-16825	delay	_
91-24	16826-16832	trials	_
91-25	16833-16834	)	_
91-26	16835-16836	.	_

Text=Six rigid-body head motion parameters and their derivatives, as well as run-wise 0 through 3rd order polynomials, were used as nuisance regressors.
92-1	16837-16840	Six	_
92-2	16841-16851	rigid-body	_
92-3	16852-16856	head	_
92-4	16857-16863	motion	_
92-5	16864-16874	parameters	_
92-6	16875-16878	and	_
92-7	16879-16884	their	_
92-8	16885-16896	derivatives	_
92-9	16897-16898	,	_
92-10	16899-16901	as	_
92-11	16902-16906	well	_
92-12	16907-16909	as	_
92-13	16910-16918	run-wise	_
92-14	16919-16920	0	_
92-15	16921-16928	through	_
92-16	16929-16932	3rd	_
92-17	16933-16938	order	_
92-18	16939-16950	polynomials	_
92-19	16951-16952	,	_
92-20	16953-16957	were	_
92-21	16958-16962	used	_
92-22	16963-16965	as	_
92-23	16966-16974	nuisance	_
92-24	16975-16985	regressors	_
92-25	16986-16987	.	_

Text=The current and preceding TR were censored if the Euclidean norm head motion distance surpassed 0.9 mm.
93-1	16988-16991	The	_
93-2	16992-16999	current	_
93-3	17000-17003	and	_
93-4	17004-17013	preceding	_
93-5	17014-17016	TR	_
93-6	17017-17021	were	_
93-7	17022-17030	censored	_
93-8	17031-17033	if	_
93-9	17034-17037	the	_
93-10	17038-17047	Euclidean	_
93-11	17048-17052	norm	_
93-12	17053-17057	head	_
93-13	17058-17064	motion	_
93-14	17065-17073	distance	_
93-15	17074-17083	surpassed	_
93-16	17084-17087	0.9	_
93-17	17088-17090	mm	_
93-18	17091-17092	.	_

Text=This choice of censoring threshold was guided by work examining motion outliers in task-based fMRI.
94-1	17093-17097	This	_
94-2	17098-17104	choice	_
94-3	17105-17107	of	_
94-4	17108-17117	censoring	_
94-5	17118-17127	threshold	_
94-6	17128-17131	was	_
94-7	17132-17138	guided	_
94-8	17139-17141	by	_
94-9	17142-17146	work	_
94-10	17147-17156	examining	_
94-11	17157-17163	motion	_
94-12	17164-17172	outliers	_
94-13	17173-17175	in	_
94-14	17176-17186	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
94-15	17187-17191	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
94-16	17192-17193	.	_

Text=GLM-2.
95-1	17194-17199	GLM-2	_
95-2	17200-17201	.	_

Text=To estimate the HRF to individual epochs of the task, a second model was run with individual regressors for cue, delay, and target epochs.
96-1	17202-17204	To	_
96-2	17205-17213	estimate	_
96-3	17214-17217	the	_
96-4	17218-17221	HRF	_
96-5	17222-17224	to	_
96-6	17225-17235	individual	_
96-7	17236-17242	epochs	_
96-8	17243-17245	of	_
96-9	17246-17249	the	_
96-10	17250-17254	task	_
96-11	17255-17256	,	_
96-12	17257-17258	a	_
96-13	17259-17265	second	_
96-14	17266-17271	model	_
96-15	17272-17275	was	_
96-16	17276-17279	run	_
96-17	17280-17284	with	_
96-18	17285-17295	individual	_
96-19	17296-17306	regressors	_
96-20	17307-17310	for	_
96-21	17311-17314	cue	_
96-22	17315-17316	,	_
96-23	17317-17322	delay	_
96-24	17323-17324	,	_
96-25	17325-17328	and	_
96-26	17329-17335	target	_
96-27	17336-17342	epochs	_
96-28	17343-17344	.	_

Text=Relevant partial trials were included as examples of the epoch in question to aid in epoch-specific HRF estimation.
97-1	17345-17353	Relevant	_
97-2	17354-17361	partial	_
97-3	17362-17368	trials	_
97-4	17369-17373	were	_
97-5	17374-17382	included	_
97-6	17383-17385	as	_
97-7	17386-17394	examples	_
97-8	17395-17397	of	_
97-9	17398-17401	the	_
97-10	17402-17407	epoch	_
97-11	17408-17410	in	_
97-12	17411-17419	question	_
97-13	17420-17422	to	_
97-14	17423-17426	aid	_
97-15	17427-17429	in	_
97-16	17430-17444	epoch-specific	_
97-17	17445-17448	HRF	_
97-18	17449-17459	estimation	_
97-19	17460-17461	.	_

Text=Cue epochs were modeled with a 1500 ms boxcar convolved with a gamma function (AFNI ’ s block 4) and scaled to have an amplitude of 1.
98-1	17462-17465	Cue	_
98-2	17466-17472	epochs	_
98-3	17473-17477	were	_
98-4	17478-17485	modeled	_
98-5	17486-17490	with	_
98-6	17491-17492	a	_
98-7	17493-17497	1500	_
98-8	17498-17500	ms	_
98-9	17501-17507	boxcar	_
98-10	17508-17517	convolved	_
98-11	17518-17522	with	_
98-12	17523-17524	a	_
98-13	17525-17530	gamma	_
98-14	17531-17539	function	_
98-15	17540-17541	(	_
98-16	17542-17546	AFNI	_
98-17	17547-17548	’	_
98-18	17549-17550	s	_
98-19	17551-17556	block	_
98-20	17557-17558	4	_
98-21	17559-17560	)	_
98-22	17561-17564	and	_
98-23	17565-17571	scaled	_
98-24	17572-17574	to	_
98-25	17575-17579	have	_
98-26	17580-17582	an	_
98-27	17583-17592	amplitude	_
98-28	17593-17595	of	_
98-29	17596-17597	1	_
98-30	17598-17599	.	_

Text=Delay epochs were modeled with a single regressor composed of a 1500 ms (short delay trials) or 6000 ms (long delay trials) boxcar convolved with a gamma function.
99-1	17600-17605	Delay	_
99-2	17606-17612	epochs	_
99-3	17613-17617	were	_
99-4	17618-17625	modeled	_
99-5	17626-17630	with	_
99-6	17631-17632	a	_
99-7	17633-17639	single	_
99-8	17640-17649	regressor	_
99-9	17650-17658	composed	_
99-10	17659-17661	of	_
99-11	17662-17663	a	_
99-12	17664-17668	1500	_
99-13	17669-17671	ms	_
99-14	17672-17673	(	_
99-15	17674-17679	short	_
99-16	17680-17685	delay	_
99-17	17686-17692	trials	_
99-18	17693-17694	)	_
99-19	17695-17697	or	_
99-20	17698-17702	6000	_
99-21	17703-17705	ms	_
99-22	17706-17707	(	_
99-23	17708-17712	long	_
99-24	17713-17718	delay	_
99-25	17719-17725	trials	_
99-26	17726-17727	)	_
99-27	17728-17734	boxcar	_
99-28	17735-17744	convolved	_
99-29	17745-17749	with	_
99-30	17750-17751	a	_
99-31	17752-17757	gamma	_
99-32	17758-17766	function	_
99-33	17767-17768	.	_

Text=Target epochs were modeled using constant and parametric terms, each convolved with a gamma function.
100-1	17769-17775	Target	_
100-2	17776-17782	epochs	_
100-3	17783-17787	were	_
100-4	17788-17795	modeled	_
100-5	17796-17801	using	_
100-6	17802-17810	constant	_
100-7	17811-17814	and	_
100-8	17815-17825	parametric	_
100-9	17826-17831	terms	_
100-10	17832-17833	,	_
100-11	17834-17838	each	_
100-12	17839-17848	convolved	_
100-13	17849-17853	with	_
100-14	17854-17855	a	_
100-15	17856-17861	gamma	_
100-16	17862-17870	function	_
100-17	17871-17872	.	_

Text=For each trial, reaction time determined the width of the constant term and the height of the parametric term.
101-1	17873-17876	For	_
101-2	17877-17881	each	_
101-3	17882-17887	trial	_
101-4	17888-17889	,	_
101-5	17890-17898	reaction	_
101-6	17899-17903	time	_
101-7	17904-17914	determined	_
101-8	17915-17918	the	_
101-9	17919-17924	width	_
101-10	17925-17927	of	_
101-11	17928-17931	the	_
101-12	17932-17940	constant	_
101-13	17941-17945	term	_
101-14	17946-17949	and	_
101-15	17950-17953	the	_
101-16	17954-17960	height	_
101-17	17961-17963	of	_
101-18	17964-17967	the	_
101-19	17968-17978	parametric	_
101-20	17979-17983	term	_
101-21	17984-17985	.	_

Text=The constant term was scaled to have an amplitude of 1.
102-1	17986-17989	The	_
102-2	17990-17998	constant	_
102-3	17999-18003	term	_
102-4	18004-18007	was	_
102-5	18008-18014	scaled	_
102-6	18015-18017	to	_
102-7	18018-18022	have	_
102-8	18023-18025	an	_
102-9	18026-18035	amplitude	_
102-10	18036-18038	of	_
102-11	18039-18040	1	_
102-12	18041-18042	.	_

Text=The same nuisance regressors and motion censoring were used as in GLM-1.
103-1	18043-18046	The	_
103-2	18047-18051	same	_
103-3	18052-18060	nuisance	_
103-4	18061-18071	regressors	_
103-5	18072-18075	and	_
103-6	18076-18082	motion	_
103-7	18083-18092	censoring	_
103-8	18093-18097	were	_
103-9	18098-18102	used	_
103-10	18103-18105	as	_
103-11	18106-18108	in	_
103-12	18109-18114	GLM-1	_
103-13	18115-18116	.	_

Text=Comparison of a reconstructed time series from GLM-2 and the observed time series of GLM-1 (Supplemental Fig.
104-1	18117-18127	Comparison	_
104-2	18128-18130	of	_
104-3	18131-18132	a	_
104-4	18133-18146	reconstructed	_
104-5	18147-18151	time	_
104-6	18152-18158	series	_
104-7	18159-18163	from	_
104-8	18164-18169	GLM-2	_
104-9	18170-18173	and	_
104-10	18174-18177	the	_
104-11	18178-18186	observed	_
104-12	18187-18191	time	_
104-13	18192-18198	series	_
104-14	18199-18201	of	_
104-15	18202-18207	GLM-1	_
104-16	18208-18209	(	_
104-17	18210-18222	Supplemental	_
104-18	18223-18226	Fig	_
104-19	18227-18228	.	_

Text=S3) suggested the epoch-based analysis of GLM-2 adequately captured primary amplitude components of the piecewise time series in GLM-1.
105-1	18229-18231	S3	_
105-2	18232-18233	)	_
105-3	18234-18243	suggested	_
105-4	18244-18247	the	_
105-5	18248-18259	epoch-based	_
105-6	18260-18268	analysis	_
105-7	18269-18271	of	_
105-8	18272-18277	GLM-2	_
105-9	18278-18288	adequately	_
105-10	18289-18297	captured	_
105-11	18298-18305	primary	_
105-12	18306-18315	amplitude	_
105-13	18316-18326	components	_
105-14	18327-18329	of	_
105-15	18330-18333	the	_
105-16	18334-18343	piecewise	_
105-17	18344-18348	time	_
105-18	18349-18355	series	_
105-19	18356-18358	in	_
105-20	18359-18364	GLM-1	_
105-21	18365-18366	.	_

Text=Voxelwise testing.
106-1	18367-18376	Voxelwise	_
106-2	18377-18384	testing	_
106-3	18385-18386	.	_

Text=In order to detect potential subtle differences in the shape of the HRF as a function of cannabis measures, omnibus group effects were examined on correct trial time courses (GLM −1), entered into a voxel-wise multivariate model (3dMVM).
107-1	18387-18389	In	_
107-2	18390-18395	order	_
107-3	18396-18398	to	_
107-4	18399-18405	detect	_
107-5	18406-18415	potential	_
107-6	18416-18422	subtle	_
107-7	18423-18434	differences	_
107-8	18435-18437	in	_
107-9	18438-18441	the	_
107-10	18442-18447	shape	_
107-11	18448-18450	of	_
107-12	18451-18454	the	_
107-13	18455-18458	HRF	_
107-14	18459-18461	as	_
107-15	18462-18463	a	_
107-16	18464-18472	function	_
107-17	18473-18475	of	_
107-18	18476-18484	cannabis	_
107-19	18485-18493	measures	_
107-20	18494-18495	,	_
107-21	18496-18503	omnibus	_
107-22	18504-18509	group	_
107-23	18510-18517	effects	_
107-24	18518-18522	were	_
107-25	18523-18531	examined	_
107-26	18532-18534	on	_
107-27	18535-18542	correct	_
107-28	18543-18548	trial	_
107-29	18549-18553	time	_
107-30	18554-18561	courses	_
107-31	18562-18563	(	_
107-32	18564-18567	GLM	_
107-33	18568-18570	−1	_
107-34	18571-18572	)	_
107-35	18573-18574	,	_
107-36	18575-18582	entered	_
107-37	18583-18587	into	_
107-38	18588-18589	a	_
107-39	18590-18600	voxel-wise	_
107-40	18601-18613	multivariate	_
107-41	18614-18619	model	_
107-42	18620-18621	(	_
107-43	18622-18627	3dMVM	_
107-44	18628-18629	)	_
107-45	18630-18631	.	_

Text=TR (15 time points) and condition (1500 ms/6000 ms delay trials) were entered as within-subject effects and cannabis measures (age of onset or total use) were entered as between-subject effects.
108-1	18632-18634	TR	_
108-2	18635-18636	(	_
108-3	18637-18639	15	_
108-4	18640-18644	time	_
108-5	18645-18651	points	_
108-6	18652-18653	)	_
108-7	18654-18657	and	_
108-8	18658-18667	condition	_
108-9	18668-18669	(	_
108-10	18670-18674	1500	_
108-11	18675-18682	ms/6000	_
108-12	18683-18685	ms	_
108-13	18686-18691	delay	_
108-14	18692-18698	trials	_
108-15	18699-18700	)	_
108-16	18701-18705	were	_
108-17	18706-18713	entered	_
108-18	18714-18716	as	_
108-19	18717-18731	within-subject	_
108-20	18732-18739	effects	_
108-21	18740-18743	and	_
108-22	18744-18752	cannabis	_
108-23	18753-18761	measures	_
108-24	18762-18763	(	_
108-25	18764-18767	age	_
108-26	18768-18770	of	_
108-27	18771-18776	onset	_
108-28	18777-18779	or	_
108-29	18780-18785	total	_
108-30	18786-18789	use	_
108-31	18790-18791	)	_
108-32	18792-18796	were	_
108-33	18797-18804	entered	_
108-34	18805-18807	as	_
108-35	18808-18823	between-subject	_
108-36	18824-18831	effects	_
108-37	18832-18833	.	_

Text=An interaction term between TR and the cannabis measure was used to identify voxels whose correct, trial-wise HRF significantly varied as a function of age of onset or total use.
109-1	18834-18836	An	_
109-2	18837-18848	interaction	_
109-3	18849-18853	term	_
109-4	18854-18861	between	_
109-5	18862-18864	TR	_
109-6	18865-18868	and	_
109-7	18869-18872	the	_
109-8	18873-18881	cannabis	_
109-9	18882-18889	measure	_
109-10	18890-18893	was	_
109-11	18894-18898	used	_
109-12	18899-18901	to	_
109-13	18902-18910	identify	_
109-14	18911-18917	voxels	_
109-15	18918-18923	whose	_
109-16	18924-18931	correct	_
109-17	18932-18933	,	_
109-18	18934-18944	trial-wise	_
109-19	18945-18948	HRF	_
109-20	18949-18962	significantly	_
109-21	18963-18969	varied	_
109-22	18970-18972	as	_
109-23	18973-18974	a	_
109-24	18975-18983	function	_
109-25	18984-18986	of	_
109-26	18987-18990	age	_
109-27	18991-18993	of	_
109-28	18994-18999	onset	_
109-29	19000-19002	or	_
109-30	19003-19008	total	_
109-31	19009-19012	use	_
109-32	19013-19014	.	_

Text=Importantly, this analysis was blind to the direction of the effect (F-test) and epoch amplitudes, such that differences as a function of a cannabis measure in any epoch could contribute to a trial-wise difference.
110-1	19015-19026	Importantly	_
110-2	19027-19028	,	_
110-3	19029-19033	this	_
110-4	19034-19042	analysis	_
110-5	19043-19046	was	_
110-6	19047-19052	blind	_
110-7	19053-19055	to	_
110-8	19056-19059	the	_
110-9	19060-19069	direction	_
110-10	19070-19072	of	_
110-11	19073-19076	the	_
110-12	19077-19083	effect	_
110-13	19084-19085	(	_
110-14	19086-19092	F-test	_
110-15	19093-19094	)	_
110-16	19095-19098	and	_
110-17	19099-19104	epoch	_
110-18	19105-19115	amplitudes	_
110-19	19116-19117	,	_
110-20	19118-19122	such	_
110-21	19123-19127	that	_
110-22	19128-19139	differences	_
110-23	19140-19142	as	_
110-24	19143-19144	a	_
110-25	19145-19153	function	_
110-26	19154-19156	of	_
110-27	19157-19158	a	_
110-28	19159-19167	cannabis	_
110-29	19168-19175	measure	_
110-30	19176-19178	in	_
110-31	19179-19182	any	_
110-32	19183-19188	epoch	_
110-33	19189-19194	could	_
110-34	19195-19205	contribute	_
110-35	19206-19208	to	_
110-36	19209-19210	a	_
110-37	19211-19221	trial-wise	_
110-38	19222-19232	difference	_
110-39	19233-19234	.	_

Text=Voxelwise testing was masked to only include voxels with a 50% or greater probability of being grey matter in the MNI-152 template and full EPI coverage in all subjects across all runs.
111-1	19235-19244	Voxelwise	_
111-2	19245-19252	testing	_
111-3	19253-19256	was	_
111-4	19257-19263	masked	_
111-5	19264-19266	to	_
111-6	19267-19271	only	_
111-7	19272-19279	include	_
111-8	19280-19286	voxels	_
111-9	19287-19291	with	_
111-10	19292-19293	a	_
111-11	19294-19296	50	_
111-12	19297-19298	%	_
111-13	19299-19301	or	_
111-14	19302-19309	greater	_
111-15	19310-19321	probability	_
111-16	19322-19324	of	_
111-17	19325-19330	being	_
111-18	19331-19335	grey	_
111-19	19336-19342	matter	_
111-20	19343-19345	in	_
111-21	19346-19349	the	_
111-22	19350-19357	MNI-152	_
111-23	19358-19366	template	_
111-24	19367-19370	and	_
111-25	19371-19375	full	_
111-26	19376-19379	EPI	_
111-27	19380-19388	coverage	_
111-28	19389-19391	in	_
111-29	19392-19395	all	_
111-30	19396-19404	subjects	_
111-31	19405-19411	across	_
111-32	19412-19415	all	_
111-33	19416-19420	runs	_
111-34	19421-19422	.	_

Text=Voxels were further constrained such that each had a main effect of TR (F-test), suggesting activation to the WM task significantly differed (positively or negatively) from baseline.
112-1	19423-19429	Voxels	_
112-2	19430-19434	were	_
112-3	19435-19442	further	_
112-4	19443-19454	constrained	_
112-5	19455-19459	such	_
112-6	19460-19464	that	_
112-7	19465-19469	each	_
112-8	19470-19473	had	_
112-9	19474-19475	a	_
112-10	19476-19480	main	_
112-11	19481-19487	effect	_
112-12	19488-19490	of	_
112-13	19491-19493	TR	_
112-14	19494-19495	(	_
112-15	19496-19502	F-test	_
112-16	19503-19504	)	_
112-17	19505-19506	,	_
112-18	19507-19517	suggesting	_
112-19	19518-19528	activation	_
112-20	19529-19531	to	_
112-21	19532-19535	the	_
112-22	19536-19538	WM	http://maven.renci.org/NeuroBridge/neurobridge#Thing
112-23	19539-19543	task	_
112-24	19544-19557	significantly	_
112-25	19558-19566	differed	_
112-26	19567-19568	(	_
112-27	19569-19579	positively	_
112-28	19580-19582	or	_
112-29	19583-19593	negatively	_
112-30	19594-19595	)	_
112-31	19596-19600	from	_
112-32	19601-19609	baseline	_
112-33	19610-19611	.	_

Text=Results were corrected for multiple comparisons using the intersection of voxelwise FDR correction (q <.05) and cluster size within the voxelwise space as defined above.
113-1	19612-19619	Results	_
113-2	19620-19624	were	_
113-3	19625-19634	corrected	_
113-4	19635-19638	for	_
113-5	19639-19647	multiple	_
113-6	19648-19659	comparisons	_
113-7	19660-19665	using	_
113-8	19666-19669	the	_
113-9	19670-19682	intersection	_
113-10	19683-19685	of	_
113-11	19686-19695	voxelwise	_
113-12	19696-19699	FDR	_
113-13	19700-19710	correction	_
113-14	19711-19712	(	_
113-15	19713-19714	q	_
113-16	19715-19716	<	_
113-17	19717-19720	.05	_
113-18	19721-19722	)	_
113-19	19723-19726	and	_
113-20	19727-19734	cluster	_
113-21	19735-19739	size	_
113-22	19740-19746	within	_
113-23	19747-19750	the	_
113-24	19751-19760	voxelwise	_
113-25	19761-19766	space	_
113-26	19767-19769	as	_
113-27	19770-19777	defined	_
113-28	19778-19783	above	_
113-29	19784-19785	.	_

Text=Cluster size thresholds were determined through a Monte Carlo simulation using AFNI ’ s 3dClustSim program with mean spatial autocorrelation parameters estimated from GLM-1 residuals.
114-1	19786-19793	Cluster	_
114-2	19794-19798	size	_
114-3	19799-19809	thresholds	_
114-4	19810-19814	were	_
114-5	19815-19825	determined	_
114-6	19826-19833	through	_
114-7	19834-19835	a	_
114-8	19836-19841	Monte	_
114-9	19842-19847	Carlo	_
114-10	19848-19858	simulation	_
114-11	19859-19864	using	_
114-12	19865-19869	AFNI	_
114-13	19870-19871	’	_
114-14	19872-19873	s	_
114-15	19874-19884	3dClustSim	_
114-16	19885-19892	program	_
114-17	19893-19897	with	_
114-18	19898-19902	mean	_
114-19	19903-19910	spatial	_
114-20	19911-19926	autocorrelation	_
114-21	19927-19937	parameters	_
114-22	19938-19947	estimated	_
114-23	19948-19952	from	_
114-24	19953-19958	GLM-1	_
114-25	19959-19968	residuals	_
114-26	19969-19970	.	_

Text=This analysis specified that 16 or more contiguous (faces touching) voxels with a single voxel threshold of p = .0018 (q <.05) for cannabis age of onset and p = .0023 (q <.05) for total cannabis use were required to achieve corrected, cluster-level alphas of less than .05.
115-1	19971-19975	This	_
115-2	19976-19984	analysis	_
115-3	19985-19994	specified	_
115-4	19995-19999	that	_
115-5	20000-20002	16	_
115-6	20003-20005	or	_
115-7	20006-20010	more	_
115-8	20011-20021	contiguous	_
115-9	20022-20023	(	_
115-10	20024-20029	faces	_
115-11	20030-20038	touching	_
115-12	20039-20040	)	_
115-13	20041-20047	voxels	_
115-14	20048-20052	with	_
115-15	20053-20054	a	_
115-16	20055-20061	single	_
115-17	20062-20067	voxel	_
115-18	20068-20077	threshold	_
115-19	20078-20080	of	_
115-20	20081-20082	p	_
115-21	20083-20084	=	_
115-22	20085-20090	.0018	_
115-23	20091-20092	(	_
115-24	20093-20094	q	_
115-25	20095-20096	<	_
115-26	20097-20100	.05	_
115-27	20101-20102	)	_
115-28	20103-20106	for	_
115-29	20107-20115	cannabis	_
115-30	20116-20119	age	_
115-31	20120-20122	of	_
115-32	20123-20128	onset	_
115-33	20129-20132	and	_
115-34	20133-20134	p	_
115-35	20135-20136	=	_
115-36	20137-20142	.0023	_
115-37	20143-20144	(	_
115-38	20145-20146	q	_
115-39	20147-20148	<	_
115-40	20149-20152	.05	_
115-41	20153-20154	)	_
115-42	20155-20158	for	_
115-43	20159-20164	total	_
115-44	20165-20173	cannabis	_
115-45	20174-20177	use	_
115-46	20178-20182	were	_
115-47	20183-20191	required	_
115-48	20192-20194	to	_
115-49	20195-20202	achieve	_
115-50	20203-20212	corrected	_
115-51	20213-20214	,	_
115-52	20215-20228	cluster-level	_
115-53	20229-20235	alphas	_
115-54	20236-20238	of	_
115-55	20239-20243	less	_
115-56	20244-20248	than	_
115-57	20249-20252	.05	_
115-58	20253-20254	.	_

Text=Epoch testing.
116-1	20255-20260	Epoch	_
116-2	20261-20268	testing	_
116-3	20269-20270	.	_

Text=Post-hoc comparisons (using GLM-2) and brain-behavior analysis were performed on the mean activation within clusters with a significant cannabis by TR interaction (as defined above in GLM-1) for cue, delay, and target epochs.
117-1	20271-20279	Post-hoc	_
117-2	20280-20291	comparisons	_
117-3	20292-20293	(	_
117-4	20294-20299	using	_
117-5	20300-20305	GLM-2	_
117-6	20306-20307	)	_
117-7	20308-20311	and	_
117-8	20312-20326	brain-behavior	_
117-9	20327-20335	analysis	_
117-10	20336-20340	were	_
117-11	20341-20350	performed	_
117-12	20351-20353	on	_
117-13	20354-20357	the	_
117-14	20358-20362	mean	_
117-15	20363-20373	activation	_
117-16	20374-20380	within	_
117-17	20381-20389	clusters	_
117-18	20390-20394	with	_
117-19	20395-20396	a	_
117-20	20397-20408	significant	_
117-21	20409-20417	cannabis	_
117-22	20418-20420	by	_
117-23	20421-20423	TR	_
117-24	20424-20435	interaction	_
117-25	20436-20437	(	_
117-26	20438-20440	as	_
117-27	20441-20448	defined	_
117-28	20449-20454	above	_
117-29	20455-20457	in	_
117-30	20458-20463	GLM-1	_
117-31	20464-20465	)	_
117-32	20466-20469	for	_
117-33	20470-20473	cue	_
117-34	20474-20475	,	_
117-35	20476-20481	delay	_
117-36	20482-20483	,	_
117-37	20484-20487	and	_
117-38	20488-20494	target	_
117-39	20495-20501	epochs	_
117-40	20502-20503	.	_

Text=Significance values were Bonferroni corrected across epochs within each cluster.
118-1	20504-20516	Significance	_
118-2	20517-20523	values	_
118-3	20524-20528	were	_
118-4	20529-20539	Bonferroni	_
118-5	20540-20549	corrected	_
118-6	20550-20556	across	_
118-7	20557-20563	epochs	_
118-8	20564-20570	within	_
118-9	20571-20575	each	_
118-10	20576-20583	cluster	_
118-11	20584-20585	.	_

Text=Covariates (Tables 1 and 2) were utilized in the same procedure as behavioral analysis (baseline and full models).
119-1	20586-20596	Covariates	_
119-2	20597-20598	(	_
119-3	20599-20605	Tables	_
119-4	20606-20607	1	_
119-5	20608-20611	and	_
119-6	20612-20613	2	_
119-7	20614-20615	)	_
119-8	20616-20620	were	_
119-9	20621-20629	utilized	_
119-10	20630-20632	in	_
119-11	20633-20636	the	_
119-12	20637-20641	same	_
119-13	20642-20651	procedure	_
119-14	20652-20654	as	_
119-15	20655-20665	behavioral	_
119-16	20666-20674	analysis	_
119-17	20675-20676	(	_
119-18	20677-20685	baseline	_
119-19	20686-20689	and	_
119-20	20690-20694	full	_
119-21	20695-20701	models	_
119-22	20702-20703	)	_
119-23	20704-20705	.	_

Text=Brain-behavior analyses were performed on mean performance measures (mean of log reaction time and mean accuracy).
120-1	20706-20720	Brain-behavior	_
120-2	20721-20729	analyses	_
120-3	20730-20734	were	_
120-4	20735-20744	performed	_
120-5	20745-20747	on	_
120-6	20748-20752	mean	_
120-7	20753-20764	performance	_
120-8	20765-20773	measures	_
120-9	20774-20775	(	_
120-10	20776-20780	mean	_
120-11	20781-20783	of	_
120-12	20784-20787	log	_
120-13	20788-20796	reaction	_
120-14	20797-20801	time	_
120-15	20802-20805	and	_
120-16	20806-20810	mean	_
120-17	20811-20819	accuracy	_
120-18	20820-20821	)	_
120-19	20822-20823	.	_

Text=Reaction time models used linear regression.
121-1	20824-20832	Reaction	_
121-2	20833-20837	time	_
121-3	20838-20844	models	_
121-4	20845-20849	used	_
121-5	20850-20856	linear	_
121-6	20857-20867	regression	_
121-7	20868-20869	.	_

Text=Accuracy models used beta regression in order to reduce the impact of mean accuracy distribution ceiling.
122-1	20870-20878	Accuracy	_
122-2	20879-20885	models	_
122-3	20886-20890	used	_
122-4	20891-20895	beta	_
122-5	20896-20906	regression	_
122-6	20907-20909	in	_
122-7	20910-20915	order	_
122-8	20916-20918	to	_
122-9	20919-20925	reduce	_
122-10	20926-20929	the	_
122-11	20930-20936	impact	_
122-12	20937-20939	of	_
122-13	20940-20944	mean	_
122-14	20945-20953	accuracy	_
122-15	20954-20966	distribution	_
122-16	20967-20974	ceiling	_
122-17	20975-20976	.	_

Text=For all epoch testing, potential influential observations were removed if Cook ’ s distance or dfbetas exceeded 1 in either the post-hoc epoch or brain-behavior model.
123-1	20977-20980	For	_
123-2	20981-20984	all	_
123-3	20985-20990	epoch	_
123-4	20991-20998	testing	_
123-5	20999-21000	,	_
123-6	21001-21010	potential	_
123-7	21011-21022	influential	_
123-8	21023-21035	observations	_
123-9	21036-21040	were	_
123-10	21041-21048	removed	_
123-11	21049-21051	if	_
123-12	21052-21056	Cook	_
123-13	21057-21058	’	_
123-14	21059-21060	s	_
123-15	21061-21069	distance	_
123-16	21070-21072	or	_
123-17	21073-21080	dfbetas	_
123-18	21081-21089	exceeded	_
123-19	21090-21091	1	_
123-20	21092-21094	in	_
123-21	21095-21101	either	_
123-22	21102-21105	the	_
123-23	21106-21114	post-hoc	_
123-24	21115-21120	epoch	_
123-25	21121-21123	or	_
123-26	21124-21138	brain-behavior	_
123-27	21139-21144	model	_
123-28	21145-21146	.	_

Text=This never resulted in more than 2 subjects being removed.
124-1	21147-21151	This	_
124-2	21152-21157	never	_
124-3	21158-21166	resulted	_
124-4	21167-21169	in	_
124-5	21170-21174	more	_
124-6	21175-21179	than	_
124-7	21180-21181	2	_
124-8	21182-21190	subjects	_
124-9	21191-21196	being	_
124-10	21197-21204	removed	_
124-11	21205-21206	.	_

Text=Mediation analysis.
125-1	21207-21216	Mediation	_
125-2	21217-21225	analysis	_
125-3	21226-21227	.	_

Text=To examine whether differences in activation could account for behavioral differences, mediation analysis was performed on epoch amplitudes that had significant, corrected associations to 1) cannabis measures and 2) WM performance (while covarying the cannabis measure).
126-1	21228-21230	To	_
126-2	21231-21238	examine	_
126-3	21239-21246	whether	_
126-4	21247-21258	differences	_
126-5	21259-21261	in	_
126-6	21262-21272	activation	_
126-7	21273-21278	could	_
126-8	21279-21286	account	_
126-9	21287-21290	for	_
126-10	21291-21301	behavioral	_
126-11	21302-21313	differences	_
126-12	21314-21315	,	_
126-13	21316-21325	mediation	_
126-14	21326-21334	analysis	_
126-15	21335-21338	was	_
126-16	21339-21348	performed	_
126-17	21349-21351	on	_
126-18	21352-21357	epoch	_
126-19	21358-21368	amplitudes	_
126-20	21369-21373	that	_
126-21	21374-21377	had	_
126-22	21378-21389	significant	_
126-23	21390-21391	,	_
126-24	21392-21401	corrected	_
126-25	21402-21414	associations	_
126-26	21415-21417	to	_
126-27	21418-21419	1	_
126-28	21420-21421	)	_
126-29	21422-21430	cannabis	_
126-30	21431-21439	measures	_
126-31	21440-21443	and	_
126-32	21444-21445	2	_
126-33	21446-21447	)	_
126-34	21448-21450	WM	_
126-35	21451-21462	performance	_
126-36	21463-21464	(	_
126-37	21465-21470	while	_
126-38	21471-21480	covarying	_
126-39	21481-21484	the	_
126-40	21485-21493	cannabis	_
126-41	21494-21501	measure	_
126-42	21502-21503	)	_
126-43	21504-21505	.	_

Text=Significance values for indirect effects were obtained using 5000 draws in a bootstrap procedure (mediation package).
127-1	21506-21518	Significance	_
127-2	21519-21525	values	_
127-3	21526-21529	for	_
127-4	21530-21538	indirect	_
127-5	21539-21546	effects	_
127-6	21547-21551	were	_
127-7	21552-21560	obtained	_
127-8	21561-21566	using	_
127-9	21567-21571	5000	_
127-10	21572-21577	draws	_
127-11	21578-21580	in	_
127-12	21581-21582	a	_
127-13	21583-21592	bootstrap	_
127-14	21593-21602	procedure	_
127-15	21603-21604	(	_
127-16	21605-21614	mediation	_
127-17	21615-21622	package	_
127-18	21623-21624	)	_
127-19	21625-21626	.	_

